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Chapter 1: Introduction 
1.1a. Metabolomics 
 The human genome is estimated to encode 30,000 genes, responsible for 
translating more than 100,000 distinct proteins [1]. The complete set of chromosomes 
and genes is referred to as the genome. The term ‘genome’ has been used for more 
than 7 decades but the term genomics was coined in 1986 by Thomas Roderick [2] 
when the whole ‘omic’ technology came into existence. Studying genomes of organisms 
was thought to give information and help understand the function of genes and would 
help to compare them among other organisms. Along with genomics, proteomics 
promised better understanding of genes and their products, proteins.  The word 
proteome is derived from a combination of protein and genome. It represents the 
comprehensive study of proteins produced by an organism in its lifetime based on its 
genome. But the proteome of an organism might change from cell to cell  based on the 
cellular environment, biochemical interactions etc while an organisms genome is 
constant. Moreover, after translation of genes to proteins, proteins can undergo various 
modifications (glycosylation, phosphorylation etc.), degradation and alternative splicing 
[2]. Thus although genomics gives us information about the genes and proteins that 
they are encoding, it does not increase our knowledge about whether or not the protein 
is going to be  part of the cellular processes or the organism’s metabolism. It is possible 
that some transcribed proteins would never be a part of the biochemical system. Thus, 
studying the proteins or metabolites that have been part of biochemical and cellular 
processes would be more specific, relevant and would give a realistic scenario about 
the changes within the system under different conditions (normal, drugs, disease, 
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toxicity etc.). With rapid advances in techniques like nuclear magnetic resonance (NMR) 
and mass spectroscopy (MS), data on metabolites, nutrients and other compounds in 
bio-fluids can be acquired precisely and over a wide range. These two techniques are 
often used for extracting data from biological samples. In 1971 Robinson and Pauling 
used Gas-Liquid Partition Chromatography to quantitate and analyze urine vapor and 
breath [3]. This was the first time that metabolites could directly be related to some 
disease condition. However, the word ‘metabolomics’, the latest ‘omic’ technology,  was 
coined for the first time in the year 1998 during analyses of the yeast genome [4]. 
Metabolomics is a comprehensive and quantitative study of the complete set of 
intracellular and extracellular metabolites produced as an end product of an organism’s 
metabolism [1]. In addition, the technique can be used to investigate the effect of any 
environmental stresses on the organism. Metabolomics may be used to investigate 
chemical composition of an organism, metabolite pattern, effect of a drug, or 
progression of disease. Cells, tissues or any body fluids can be used for this purpose. 
As such body fluids such as urine, saliva, tears can be obtained in a non-invasive 
fashion, adding to it attractions [5].  One of the important attributes of metabolomics is to 
identify a molecule or a molecular signature (i.e., set of molecules) that is responsible 
for any change in the physiology of an organism under a particular stress or effect of an 
external agent. It provides information and deepens our knowledge of human health, 
interaction of drugs, toxicity, nutrition etc. and the effects of these factors on the 
genome. Figure (1.a.) shows a schematic diagram of the interaction between the 
different expressions of omic technologies and figure (1.b) shows the traditional linear 
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view of biochemical pathways as compared to a scale free (more realistic) metabolite 
pathway. 
Research in the field of human biochemistry has been conducted for over a 
century. However we still have lots of dauntingly complex problems as the research was 
largely focused on understanding enzymes and linear pathways. Metabolomics might 
help to solve problems related to specific metabolites by integrating or connecting 
different biochemical pathways (scale free). Qualitative and quantitative metabolomic 
analyses provide a view of the biochemical status of an organism under specific 
conditions. The whole idea of metabolomics is to have a better understanding of how 
the human body reacts to different endogenous and/or exogenous agents with the help 
of other branches of science. The human metabolome can be influenced by exogenous 
(diet, drugs, stress etc) and endogenous factors (body composition, age, gender, health 
status etc.) which may vary amongst individuals (figure 1-2). Thus taking all these 
factors in consideration makes it a unique and individualized (subjective) approach to an 
otherwise broader problem. 
Our knowledge of how an organism works at the molecular level is still quite 
limited. There are 20% to 40% orphan genes (genes with no known function) and these 
were not lost during evolution so it is possible that these genes have some cellular 
functions [6]. Metabolomics even takes into consideration the function of these genes 
and the way they might be interacting with the endogenous and exogenous factors. 
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Figure1 (1a) General schematic of the omic organization. The general flow of information is from genes 
to transcripts to proteins to metabolites to function (or phenotype); whilst vertical arrows indicate 
interactions regulating respective omic expression. (1b) Traditional linear view of a metabolic pathway 
and ‘‘scale free’’ connections in a metabolite neighborhood. (adapted from [6]). 
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Fig.1-2 Exogenous and endogenous factors likely to influence the human nutritional metabolome [7].    
Metabolmics investigates the metabolism of an organism and its reaction to different exogenous and 
endogenous factors (adapted from [2]). 
 
 
 
 
 
 
 
 
 
 
 
 
Almost all diseases cause metabolic dysregulations, the extent of which differs 
among individuals due to differences in how they respond to the same stress. 
Exogenous Factors Endogenous Factors 
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Metabolomics could help in interpreting difference between individuals and thus could 
help in personalized medicine or nutrition. It is a tool which can give us information 
about metabolites that can indicate disease even before symptoms become apparent / 
visible. Pre-symptomatic detection of potential disease would be a huge step in 
healthcare and medical research field. One such example is the relation between 
sarcosine and prostate cancer progression. High–throughput liquid-and-gas-
chromatography-based mass spectrometry was used to detect and profile 1,126 
metabolites from tissues, urine and plasma samples. From this metabolomic study it 
was concluded that high levels of sarcosine present in body fluids can now be linked to 
higher risk of prostate cancer [8]. With metabolomics one can produce complete 
compositional representations of individual biological samples that can be compared 
between individuals and between different data acquisition techniques (genomics, 
proteomics, transcriptomics, biochemical pathways). Approximately all metabolites are 
present virtually in all tissues and fluids; it is usually the concentration of the metabolites 
that distinguishes between different phenotypes[9]. Therefore, the techniques to extract 
data from samples and then to process the acquired data must be highly specific and 
accurate. One of the advantages of metabolomics is that there may be more than one 
unique way to detect the same metabolite. The technique/s used for detection of a 
particular metabolite will depend on the physio-chemical or biological properties of that 
particular metabolite. Table 1 below shows various commonly used techniques for 
detection of metabolites. 
 
Techniques Physiochemical / Biological Property 
Mass spectrometry Mass 
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Table 1-1. Various techniques for detection the metabolites 
The table shows techniques used to detect metabolite of interest. Specific techniques may be 
selected based on the chemical or biological properties of the metabolites of interest. Some of the 
metabolites might need extra step of extraction or separation depends on the source and nature of the 
metabolite of interest. If a metabolite is from plant origin, or mixture of compounds, or found in bound form 
in nature, the extraction and or separation step might be required.  
 
 
 
  
 
 
 
 
 
 
 
 
 
1.1b. Nuclear Magnetic Resonance (NMR) 
Infrared spectroscopy Rotation, vibration 
Fluorescence spectroscopy Energy absorbance   
NMR, ESR Spin 
Gas chromatography Volatility 
Reverse-Phase Liquid Chromatography Hydrophobicity   
Capillary electrophoresis, Ion exchange   
chromatography 
Charge 
Size exclusion chromatography Size 
FRET in vivo imaging Protein folding 
Histochemistry, antibodies Protein binding 
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NMR was first developed in1946 by research groups at Stanford and M.I.T (USA) 
[10]. It is used to determine the chemical structure and concentration of compounds 
based on the nuclear magnetic properties of the atoms. Nuclei having odd spin number 
such as 1 H, 13 C, 31 P, 15 N, 19 F is commonly used.  When an external magnetic field is 
applied, the magnetic moment of the nucleus aligns itself with the applied field to create 
different energy levels. Transitions of atomic nuclei between these energy levels over a 
period of time is recorded as free induction decay (fid) files.  Since these fid files are 
time domain signal files, it is very difficult to differentiate between spectra from different 
compounds so, the fid files are further transformed by Fourier transformation (Ft) 
(mathematical algorithm) to a frequency domain[10].  After Ft the acquired spectrum 
can be resolved into different peaks arising from different compounds or metabolites.  
Different atoms or nuclei (protons) have different electronic environment around 
them depending upon the number of electrons present in the atom. When magnetic field 
is applied, difference in electronic environment around the nuclei causes slight 
differences in the magnetic field felt by specific protons.  The stronger the electronic 
environment, the more protected or shielded the nucleus is. More shielding results in 
higher external magnetic field settings and the signal is said to be ‘upfield’. On the other 
hand, a downfield signal implies protons are less protected or de-shielded. The position 
of a specific proton signal from a particular molecule or metabolite is determined by the 
amount of shielding. The position of signal in the NMR spectrum is referred to a 
chemical shift (ppm). The chemical shift position (ppm) of some common functional 
groups is shown in figure 1-3. 
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The NMR spectrum or signal corresponds to the concentration of that compound 
present. The characteristic signal intensity changes linearly with change in 
concentration[11]. Thus, signal intensities gives direct information about the relative 
concentrations of different compounds in a complex mixture e.g. biofluids, tissues etc. 
 The techniques such as NMR used for metabolomics generate huge data-
sets which are almost impossible to analyze using any simple statistics. Thus, there is a 
need to develop more sophisticated statistical or data analysis tools. Over a period of 
time a number of tools have been developed for multivariate data analysis (MVDA). 
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Figure 1-3. Schematic Representation of chemical shift of different functional groups. 
 The NMR spectrum is divided from 0 to 12 ppm. The signal from trimethylsilane (TMS) is 
observed at 0 ppm.  TMS is heavily shielded by electrons thus it is upfield of the spectrum.  All the NMR 
signals from the metabolites will be downfield from The TMS signal because the central silicon atom in 
TMS being more electropositive than C (in metabolites) shields the electrons to a greater extent. Since all 
the methyl groups on TMS have the same electronic environment only one signal or peak is observed. 
Thus it is used as a reference indicator. As we go from right side of the spectrum to the left, the atoms are 
less shielded thus we move from upfield to downfield (adapted from[10]). 
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1.1c. Multivariate Data Analysis (MVDA) 
MVDA is a powerful tool for the analysis of data sets containing a large number 
of variables. It shows the correlation between huge data sets and a target variable. It 
helps to distinguish between signal and noise. It visualizes the correlation between 
variables in complex or large data sets (e.g., thousands of signals in NMR spectra) in 
relation to a target variable such as disease status. It has mainly two types 1) 
Unsupervised and 2) supervised MVDA. 
Unsupervised methods determine patterns within the data sets without any prior 
knowledge about the data sets. A common example is principle component analysis 
(PCA). PCA generates a summary from a huge data set based on how the observations 
are different or similar to each other. PCA is a direct representation of the data set. In 
PCA, huge set of related large variables are transformed to small uncorrelated variables 
known as principle components (PC).  PC show maximum variability in the data set. 
These PC are compared in multidimensional space to corresponding score values (e.g. 
corresponding animal, sample). The data is visualized as a PCA score plot where each 
score is one observation or in the case of NMR one score is one NMR spectrum. The 
contribution of each individual variable to PC can be calculated as a loading plot. 
Loading plots represent the variables that are responsible for clustering or differentiating 
between the groups [12].  
Supervised MVDA methods determine the patterns in the data sets based on 
some knowledge about the data sets. In supervised methods one has to feed specific 
information about the data sets e.g. categorize the data sets into different groups etc. 
Partial least square (PLS) and PLS discriminant analysis (PLSDA) are some of the 
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examples of supervised MVDA. The information is fed to the software about the 
different groups or different variables present in the data set.  PLS is a powerful tool.  
Apart from using information from NMR data sets it uses different types of information 
(biochemical, histological, DNA fragmentation information etc.) as the y-parameter and 
establishes correlation between the existing data set e.g. NMR data as x-parameter. 
PLS helps to determines whether or not the correlation exists between the two data sets 
which otherwise would be considered unrelated. 
PLS-DA maximizes the differences between groups observed in unsupervised 
PCA. It creates a dummy y-parameter and then uses the information provided to 
maximize the differences established by PCA.  
In short, MVDA gives useful information about the variability and or similarity of 
the huge data sets. In our study we compared the NMR spectra from hamster urine 
samples using PCA and PLS. However, MVDA can not quantitate the variables. For that 
we quantified the metabolites using the chenomx NMR Suite 5.1 (NMR data only), a 
NMR metabolite database. 
1.1d. Metabolite quantification (Chenomx) 
Chenomx is a metabolite database software that quantifies the metabolites by 
comparing the acquired data set or NMR signal intensities to  pre-existing signals from a 
compound library of known concentration. Previously quantifying or locating metabolites 
from the NMR spectra was a tedious job but with the help of Chenomx software it has 
become much easier to locate and quantify the metabolites. Chenomx has a database 
of 292 quantified urinary metabolites [13]. The database has libraries for different types 
of NMR magnets and different pH ranges. Once the metabolites are quantified, they can 
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be exported to excel as a text file. The metabolites can be traced back to the pathways 
that they are involved in. The software supports KEGG (Kyoto Encyclopedia of Genes 
and Genomes) which is an online free website that explains all the known pathways that 
particular metabolite of interest is part of. (http://www.genome.jp/kegg/) 
 The metabolomic approach used in this study is shown in figure 1-4. Animals 
were selected. Urine was collected weekly. NMR was conducted on the urine samples. 
The NMR data was analyzed using MVDA SIMCA P+ software. The metabolites were 
quantified with the help of NMR metabolite database software (chenomx) and then the 
quantified metabolites were validated by MVDA.  
To summarize, metabolomics is a quantitative and qualitative analytical 
technique that provides comprehensive information about metabolites or small 
molecular weight compounds. It is non–invasive and can virtually use any body fluids 
(urine, plasma, saliva, sweat, tears ) and/ or tissues. Metabolites can be detected based 
on any of their physiochemical or biological properties which provide various methods 
and more range. It can be used to asses early biomarkers, distinguish between healthy 
and diseased states, carry out and evaluate toxicity studies, nutritional interaction etc. It 
is a relatively new field in medicine and pharmacology which potentially will allow for 
better understanding of human diseases, including cancer. In the current study, we 
used metabolomics as a tool to evaluate the changes in metabolism produced during 
the progression of lung cancer and the effect of dietary intervention (with curcumin) on 
that progression. 
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1.2a. Cancer: 
Cancer is the second leading cause of death in the Unites States, after 
cardiovascular disease [14]. Figure 1-5 compares the death rates of different chronic 
diseases over. In 1950 cancer deaths were 194 per 100,000 deaths and in 2005 the 
number was still 184. In contrast heart disease was responsible for 587 deaths per 
100,000 deaths in 1950 was significantly reduced to 211 by the year 2005, indicating 
the slow progress in prevention of the disease. Tumorigenesis results from the 
accumulation of numerous sequential mutations and alterations in nuclear and 
cytoplasmic molecules[15], resulting in uncontrolled growth and spread of abnormal 
cells. Tumorigenesis is a result of a multistep process that involves three phases: 
initiation (normal cell  transformed, initiated cell), promotion (initiated 
cellpreneoplastic cell), and progression (preneoplastic cell  neoplastic cell) [16].  
The normal cell can be transformed to neoplastic cells either by exposure to 
carcinogens or repeated genetic damage caused by oxidative stress, chronic 
inflammation or hormonal imbalance. It is a multi-factorial disease caused and initiated 
by one or more factors and then later joined by a sea of signal molecules making it 
difficult to cure and target a specific molecule responsible for the disease.   
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Figure 1-4. Metabolomic Approach 
 The metabolic approach used for the curent study. NMR was used as a technique to 
acquire the data. MVDA was conducted with SIMCA software and metabolite concentration was 
quantified with the help of NMR urine database and software (chenomx). 
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In the U.S. cancer prevalence is expected to increase in the next few decades, 
because the population is aging, and cancer incidents increase proportionally with age. 
The therapies that are currently available have a high toxicity level, major side-effects, 
do not promote long term effectiveness, and are very expensive, being unaffordable to 
some patients. Based on a review by Yabroff et al, in 2004 cancer care for US patients 
cost roughly about $72 billion, with higher costs for lung and colorectal cancer 
compared with breast and prostate cancer [17]. 
Chemotherapy treatments have adverse reactions such as acute and delayed 
nausea, mouth ulcerations, fatigue, nerve damage, blood clots, anemia, and mild 
impairments due to the high level of toxicity. Also, long term chemotherapy treatment 
can amplify the risk for developing other types of cancers.[18] Therefore, it is important 
to adopt a new approach which can be used simultaneously with the currently available 
treatment so as to reduce side effects and increase the effectiveness of the drug.  
Different studies have shown that the predominance of chronic diseases is not 
related to the genetic makeup of the individual, but are linked to certain lifestyles and 
environments. A diet rich in fruits and vegetables showed a decrease in incidence of 
cancers of stomach, esophagus, lung, oral cavity and pharynx, endometrium, pancreas, 
and colon, according to 206 human epidemiologic studies and 22 animal studies 
conducted in the last decade.[14] Because of the complexity of the disease, cancer in 
particular is being studied more intensely, and several new technologies can now 
evaluate the molecular changes that occur during developmental of this disease.  
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Change in the US Death Rates* by Cause, 
1950 & 2005
* Age-adjusted to 2000 US standard population.
Sources: 1950 Mortality Data - CDC/NCHS, NVSS, Mortality Revised.
2005 Mortality Data: US Mortality Data 2005, NCHS, Centers for Disease Control and Prevention, 2008.
Heart
Diseases
Cerebrovascular
Diseases
Influenza &
Pneumonia
Cancer
1950
2005
Rate Per 100,000
 
Figure 1-5. Comparison between the changes in death rates of different chronic 
diseases. 
 
The figure compares the death rates of different chronic diseases and their 
decrease over more than 50 years of time (data collected by CDC). In spite of research 
and so many expenses spent in finding the cure for cancer, the cancer death rate has not 
changed much over the period of more than 50 years as compared to rates of other 
major chronic diseases, which decreased substantially during this period. 
 
 
 
 
 
 
  
 
18
Gene nutrient balance plays an important role in many diseases as depicted in  
figure 1-6. The figure shows the balance between the energy expenditure and energy 
intake. If the scale tips towards the left side (portraying energy intake) it implies that a 
person is at more risk of chronic diseases [1]. Apart from genetic factors and others 
involved with the cancer, the lifestyle has major effect on health too.  Thus, diet plays a 
major role in cancer prevention. 
A new approach in prevention and treatment of cancer is associated with diet, 
and the goal is to prevent carcinogenesis. Diet and dietary components can alter the 
risk of disease development by modulating multiple processes involved with onset, 
incidence, progression, and/or severity; food components can act on the human 
genome, either directly or indirectly, to alter the expression of genes and gene products;  
diet could potentially compensate for or accentuate effects of genetic polymorphisms; 
and  the consequences of a diet are dependent on the balance of health and disease 
states and on an individual’s genetic background [1]. Figure 1-7 shows some of the 
common molecular targets of dietary agents. Dietary agents have different roles 
depending on the source of the dietary agent. A particular dietary agent can show all or 
some of the properties illustrated in figure 7. Dietary agent molecules down regulate all 
protein kinases, anti-apoptotic proteins, molecules involved in metastatsis and up 
regulate apoptotic proteins etc.  
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Figure 1-6 : Certain genetic polymorphisms can shift the balance of energy intake and energy 
expenditure and thereby influence bioenergetics and obesity. Higher energy intakes, a low 
polyunsaturated-to-saturated fat ratio, insulin resistance, and a sedentary lifestyle leading to 
obesity are risk factors for chronic diseases, such as heart disease, diabetes, and cancer, 
depicted when the scale is sloping downward. The right side of the scale portrays lifestyle 
including physical activity and a diet rich in whole grains, fruits, vegetables, and soy protein, 
which are associated with less risk for obesity and chronic disease (adapted from [1]). 
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Figure 1-7. Molecular targets of dietary Agents 
 The figure shows the effect of dietary agents found in common plants, fruits and 
vegetables and its effect on the molecular signals. These molecular targets could be involved with one or 
more than one disease. The down arrow means down regulation of that particular signal molecule and up 
arrow shows up regulation. These dietary agents help prevent or cure the disease without causing any 
serious harmful side effects thus making them potential drug for that particular disease (adapted from 
[14]). 
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Cancer cells exhibit a high rate of metabolism using glucose as a primary 
substrate. Glucose comes from the diet. Therefore, it is likely that tumor cells’ sensitivity 
to exogenous and endogenous factors determining growth and differentiation is deeply 
hidden in the metabolic network supplying essential substrates for de novo 
macromolecule synthesis. Thus food plays an important role in providing the substrate 
for different reactions. All pathways in the network depend on one another via substrate 
sharing and channeling by regenerating shared co-factors that participate in oxidation 
degradation and reductive synthesis [19]. If an early diagnosis can be made, at a 
preneoplastic stage, before angiogenesis, invasion and metastases occur, there is a 
greater chance of improving survival and this may be achieved by metabolomics.  
Before any disease could arise there are biochemical changes within the body. These 
biochemical changes can be detected through any body fluid. Whatever metabolite is 
detected in urine or plasma is known to have been a part of some biochemical process 
at some point of time. Comparing metabolite profile of cancer patient and normal person 
would give information about the metabolites present between the two. Metabolomics 
would differentiate and quantitate metabolites between the two profiles which could then 
be used as early biomarkers.  
 
1.2b. Lung Cancer: 
Lung cancer is the leading cause of cancer deaths in the United States and 
worldwide, and the most common type of cancer diagnosed in men, second only to 
breast cancer in women. The common known causes of lung cancer are smoking which 
accounts for 87%, second hand smoke, exposure to substances such as arsenic, 
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asbestos, radioactive dust (radon), environmental factors and genetic changes.  The 
estimated statistics for 2008 in United States was approximately 215,000 new cases, 
and about 168,000 deaths. The major obstacle in any cancer or lung cancer is that it 
progresses undetected (asymptomatic) till it has metastasized e.g. the common 
symptoms for lung cancer are persistent cough, chest pain, coughing up blood, 
hoarseness, weight loss, fatigue and recurrent respiratory infections (such as 
pneumonia). All these symptoms can be related to some other respiratory disease and 
not specifically to lung cancer.  
Lung cancer is a malignant tumor that forms in tissues of the lung, usually in the 
cells lining air passages. Based on histological differences under a microscope, two 
main types are: small cell lung cancer (SCLC), accounting for about 15 % of the 
patients,  and non-small cell lung cancer (NSCLC), which include types of squamous 
cell carcinoma, adenocarcinoma ( including the noninvasive type of bronchioloalveolar 
carcinoma), and large cell carcinoma, and accounts for approximately 85 % of the 
patients [20]. Following the same pattern as other epithelial malignancies, from 
histopathological and biological perspective, lung cancer is a highly complex neoplasm 
and is believed to arise after a series of progressive pathological changes, identified as 
preneoplastic or premalignant lesions [20]. There are three major morphologic types of 
preneoplastic lesions of the bronchial epithelium identified recently by the World Health 
Organization (WHO) such as squamous dysplasia (SD) and carcinoma in situ (CIS), 
atypical adenomatous hyperplasia(AAH), which can be the precursor for 
adenocarcinoma, and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 
(DIP- NECH), which may progress to carcinoid [20].  
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Further research in the area may provide new methods for detecting the 
preneoplastic lesions and diminish the development of invasive lung cancer. The lung 
cancer death rate is 31%, for men and 26% for women respectively, both ranking 
number one in cancer mortality rate. (American Cancer Society. Cancer Facts & Figures 
2008.) Thus, to reduce the mortality rate, cancer incidence and improve the survival 
time of lung cancer, new techniques and approaches must be developed to diagnose 
and treat pre-invasive lesions. Working closely with different ‘omic’ technologies and 
integrating then would help to understand cancer or any disease in a better way.  There 
are many approaches for ameliorating cancer and health. One of the approaches is diet 
and gene interaction. There are many examples of nutrients acting as or on 
transcriptional factors that modify gene expression. Effects of various functional foods 
(neutraceuticals) on cancer have been very well documented [21-23]. Thus, 
Isothiocyanates, bioactive compounds in cruciferous vegetables were shown to reduce 
the risk of lung cancer by 22%  in comparison to those who did  not consume 
cruciferous vegetables [24]. 
In spite of extensive research in cancer treatment there have been lots of drugs 
that looked promising initially but then later had one or more harmful side effects. One 
of the cures was introduction of (poisonous) mustargen in 1941. Chemotherapy was 
introduced in 1971 and targeted drug therapy in 1991[25].  
The number of approvals for current anti-cancer drugs  from U.S. Food and Drug 
Administration (FDA) determines the progress of cancer research. There have been 
very few approvals in 1970, seven in 1987, sixteen in 1996, twenty one in 1998 and 
twenty eight in 2006. Out of these FDA approved anticancer drugs more than 70% can 
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be traced back to have plant origin, which were traditionally known be used as ancient 
remedies for various ailments [24]. 
In this study we used metabolomics as a tool to study changes in urinary 
metabolomic profile due to dietary intervention with curcumin in a lung cancer model. 
 
1.3. Curcumin : 
More than 2500 years ago, Hippocrates brought to attention the importance of 
various compounds found in food, his advice being” let food be thy medicine and 
medicine be thy food” [14]. The abundance of vitamins, minerals, and dietary fiber in all 
fruits and vegetables has been known for a long time, but new research has found that 
they also contain polyphenols, terpenes, alkaloids, and phenolics that can provide many 
health benefits beyond basic nutrition. For the last decade research has shown that 
numerous agents found in fruits and vegetables can interact with different cell-signaling 
pathways at multiple levels that are associated with the risk for several types of cancer. 
The dietary phytochemicals that proved to be most effective against cancer include 
Curcumin (turmeric), resveratrol ( red grapes, peanuts, berries), genistein ( soybean), 
allicin ( garlic), lycopene (tomato), 6-gingerol (ginger), ellagic acid (pomegranate), 
catechins (green tea), beta carotene (carrots), ursolic acid (apple, pears, prunes), 
indole-3-carbinol (cruciferous vegetables), and dietary fiber[14]. Because these 
phytochemicals are derived from natural sources, they are considered 
pharmacologically safe [26], well tolerated, and a dose-limiting toxicity has not been 
registered[16]. The bioactive compound present in plants may interact with one 
condition (disease) or more than one condition. The bioactive compounds or 
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phytochemicals may interact with carcinogenesis, hormone regulation, cell 
differentiation, DNA repair, apoptosis, cell growth cycle and inflammatory response. The 
more pathway a phytochemical is involved in, the broader the spectrum it has to treat or 
prevent the condition (Figure 1-8). 
Curcumin (diferuloylmethane) is a hydrophobic, low molecular weight polyphenol 
derived from the dried ground rhizome of the herb Curcuma longa (turmeric), used in 
Asian medicine since the second millennium BC [27]. The turmeric plant is associated 
with Curcuma botanical group, a member of the Zingiberaceae family of herbs [28]. 
Turmeric is mainly grown in Indian subcontinent, Southeast Asia, China, and Japan, but 
is also recognized worldwide under different names, like: Kurkum in Arabic, Curcuma in 
French and German, Koren in Russian, and Kourkoumi in Greek [29]. The dried 
rhizome of the turmeric is an affluent source of curcuminoids: curcumin, 
demethoxycurcumin( curcumin II), bisdemethoxycurcumin ( curcumin III), and the latest 
compound identified, cyclocurcumin [28].  
Besides curcuminoids, proteins, carbohydrates, essential oils and trace minerals 
make up the composition of turmeric. The major components of commercial curcumin 
are approximately 77% diferuloylmethane, 17% demethoxycurcumin, and 3% 
bisdemethoxycurcumin [30]. It is a yellow-orange crystalline powder, soluble in ethanol, 
dimethylsulfoxide, and acetone, but insoluble in water and ether[31]. 
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Figure 1-8:  Bioactive food components can influence genetic and epigenetic events 
associated with a host of disease processes (adapted from[1]). 
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The molecular formula of curcumin is C21H20O6 , a melting point of 183°C and 
molecular weight of 368.37 g/mol[29], and it has an absorption maxima of 420nm [30]. 
Figure 1-9 shows different types of curcuminoids present in turmeric. Curcumin is the 
most abundant (77%) form with tetrahydrocurcumin being the least abundanr. The main 
difference between these curcuminoids is the level of conjugation and the attached 
methoxy functional group. 
In Ayurvedic medicine, the science of long life, curcumin was well recognized 
and appreciated for its health-promoting effects. It was considered a cure for jaundice, 
gas, colic, and an appetite suppressant, used for liver disorders, toothaches, chest 
pains, to heal wounds, and lighten scars.[30] In traditional medicine, curcumin was used 
for various respiratory conditions (asthma, bronchial hyperactivity, allergy), anorexia, 
rheumatism, sprains and swelling, diabetic wounds, sinusitis, cough [29]. It acts at all 
the three stages of cancer which makes it versatile in terms of mechanism of action. 
Figure 1-10 depicts this property. Curcumin can act at the first level before the normal 
cells are transformed to tumor cells. It can also act at the second stage (tumor cells) by 
inhibiting the proliferation of the tumor cells. If there is tumor growth curcumin inhibits it 
from spreading or invading other tissues. Thus, this unique property of curcumin to act 
on all the three stages of tumorigenesis makes it a potential preventative dietary agent. 
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Tetrahydrocurcumin
*  Indicates potential sites of conjugation
Indicates absence of methoxy (OCH3) group
Hexahydrocurcumin
Bisdemethoxycurcumin
3% less active
Demethoxycurcumin
17 %
Curcumin
77%
 
Figure 1-9. Different types of Curcuminoids. 
 Figure shows different types of curcumnoids present in the turmeric plant. Curcumin 
being the most abundant (77%) and followed by demethoxycurcumin (17%).  The main 
differences between these curcuminoids is the level of conjugation and attached methoxy 
functional group which could be important factor in determining the bioactivity of that particular 
curcuminoid. 
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Figure 1-10. Anti-tumor properties of curcumin. 
 
 The figure depicts the mechanistic action of curcumin acting at all the important and 
crucial steps of cancer progression. The fact, that curcumin can act at the first step of initiation or 
transformation makes it better than other phytochemicals and anti cancer drugs. Sooner the 
curcumin interacts with factors responsible for progression of cancer, better it is for the 
alleviation of disease (adapted from [28]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Curcumin 
Transformatio
n 
Proliferatio
n 
Invasion Normal 
Cells 
Tumor  
Cells 
Tumor  
Growth 
Tumor 
Metastasis 
  
 
30
The antioxidant, anti-inflammatory, antimicrobial, hepatoprotective,  antiarthritic, 
anticarcinogenic, and possibly chemotherapeutic properties of curcumin have been 
widely studied [27].  It is well recognized that unregulated inflammation results in 
chronic diseases, and curcumin strongly demonstrates anti inflammatory properties. 
Inflammation works as a key regulator in promotion of transformed cells, by supplying 
them with proliferating signs or by preventing apoptosis [16]. The anti-inflammatory 
effect of curcumin is known to be achieved by inhibiting cyclooxygenase-2(COX-2), 
lipoxygenase (LOX), and inducible nitric oxide synthase (iNOS), which are important 
enzymes in the inflammatory progression [32]. 
Multiple studies have shown that curcumin can alter numerous targets, including 
different enzymes (MMP, iNOS, GST, and ATPase), growth factors(EGF, NGF, HGF, 
and PDGF), growth factor receptors, transcription factors (e.g., NF-kB, STAT3, AP-1, 
NRF-2, PPAR-c, and HIF-1), kinases (EGFR, ERK, JAK, and AAPK) , cytokines (TNF, 
IL, MIP, and MCP), and genes regulating apoptosis, either by up or down-regulation 
[25]. (Figure 1-11) 
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Figure 1-11. Molecular targets of curcumin. 
 The figure shows different molecular targets that are influenced by the curcumin. It 
interacts with receptors, growth factors, kinases, enzymes etc. The molecular targets shown in blue 
indicate upregulation of those molecules by curcumin and the rest, the one in red indicates down 
regulation. The molecular targets that are in blue are known to alleviate cancer.(adapted from [30]). 
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AIM OF THE STUDY 
The long term goal or overall goal of the current study was to use the 
metabolomic approach to establish a signature of lung cancer and thus evaluate 
presymptomatic biomarkers for this highly prevalent and aggressive cancer. In this 
study, we evaluated the effect of a dietary agent, curcumin as a preventative or 
therapeutic agent against lung cancer. We hypothesized that the preventative and/or 
therapeutic effect of curcumin against lung cancer in a hamster model would be 
reflected as a change in their urinary metabolomic profiles. In addition, since curcumin 
has been reported to protect against DNA damage by reducing an oxidative stress, we 
investigated the underlying mechanisms of curcumin in prevention of lung cancer in a 
hamster model, using metabolomic approach.  
In order to test the hypothesis, the following specific aims were established  
Specific Aim 1: To determine the anti cancer effect of curcumin on lung cancer 
in a in cancer - induced Golden Syrian hamster animal model. 
 Specific Aim 2: To study changes in urinary metabolomic profile with cancer 
progression using 1D proton NMR. 
Specific Aim 3: To determine the potential early biomarkers for lung cancer 
using metabolomic approach. 
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CHAPTER 2 : MATERIAL AND METHODS 
2.1. Animals  
Male 8 week old Golden Syrian hamsters (n = 52) weighing between 80-100 g 
were purchased from Charles River Labs (Wilmington, MA). The animals were housed 
individually in solid bedding cages and maintained with a 12-h light/12-h dark cycle 
under standard conditions as recommended by the Division of Laboratory Animal 
Resources (DLAR) Wayne State University (under constant temperature of 72 º F and 
humidity between 35-50%). Food and water was provided ad libitum and animals were 
allowed to acclimatize to the environment for one week prior to any experimentation. 
The protocol was approved by the Animal Investigation Committee of Wayne State 
University. 
 
2.2. Diet  
The control diet (purified casein diet) and experimental diet (2% curcumin) were 
purchased from Dyets Inc. (Bethlehem, PA) in pellet form.  The experimental diet was 
prepared by mixing purified casein hamster diet with curcumin, with a final concentration 
of curcumin of 2% w/w. Both types of diet were kept at -20ºC, and sufficient diet was 
removed weakly for the hamsters and kept refrigerated.Table.2 show composition of the 
diets. 
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Regular 2% Curcumin 
Ingredient kcal./gm grams/kg kcal./kg kcal./gm grams/kg kcal./kg 
Casein 3.58 220 787.6 3.58 220 787.6 
Dextrose 3.8 160 608 3.8 160 608 
Cornstarch 3.6 460.9 1659.24 3.6 440.9 1587.24 
L-Arginine 4 1 4 4 1 4 
L-Tryptophan 4 1.1 4.4 4 1.1 4.4 
Cellulose 0 50 0 0 50 0 
Corn Oil 9 60 540 9 60 540 
Mineral Mix 
(#260001) 
0 35 0 0 35 0 
Vitamin Mix 
(# 360001) 
3.84 10 38.4 3.84 10 38.4 
Curcumin 0 0 0 -- 20 -- 
Choline 
Bitartrate 
0 2 0 0 2 0 
  
Table 2-1. Composition of the Experimental Diet 
From Recommendations by NRC "Nutrient Requirements of Laboratory Animals" 
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2.3. Cancer induction  
Lung cancer was induced by a chemical carcinogen N-nitrosobis (2-oxopropyl)-
amine (BOP) purchased from Nacalai Tesque Inc. (Kyoto Japan). BOP was injected 
(10mg/kg body weight) subcutaneously, weekly for 12 weeks, Controls were injected an 
equal volume of saline. 
 
2.4. Experimental protocol/outline 
 Animals were randomly divided into three groups treatment (n = 20), prevention 
(n = 20) and control (n = 12). The whole duration of study was 24 weeks. 
2.4.a. Treatment group Treatment group was further divided into two groups T0 (n=10) 
and T2 (n=10). T2 and T0 both were subcutaneously injected with BOP (10mg/kg body 
weight) and both were fed control diet for first 12 weeks. After 12 weeks of injection, T2 
group was given 2% curcumin in their diet for 12 weeks while T0 group was still fed 
control diet (no curcumin). After 12 weeks of BOP injections both the groups received 
saline for remaining 12 weeks of the study. 
2.4.b. Prevention group This group was further divided in to two groups P0 (n=10) and 
P2 (n=10). Both the groups P0 and P2 got saline injections for first 12 weeks. After first 
12 weeks P0 and P2 were subcutaneously injected with BOP (10mg/kg body weight). 
Group P0 was never fed any curcumin in their diet while  group P2 was fed 2% 
curcumin throughout the study starting from week 1st. 
2.4.c. Control group This group was further divided in to two groups C0 (n=6) and C2 
(n=6). Both the groups C0 and C2 were subcutaneously injected saline throughout the 
study starting from week 1. None of the groups never received any BOP. Group C0 was 
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fed control diet throughout the study (no curcumin) while group C2 was fed 2% 
curcumin in their diet throughout the study. 
Figure 2-1 describes shows the experimental design groups. Treatment group T0 
was subcutaneously injected with chemical carcinogen (BOP) for first 12 weeks and no 
curcumin in the diet throughout the study and T2 was given BOP for the first 12 weeks 
and 2% curcumin in the diet from week 12 till the end of the study (24th week). 
Prevention group P0 was neither injected with BOP, nor given any curcumin in the diet 
throughout the study while as group P2 was given 2% curcumin in their diet throughout 
the study. BOP was injected subcutaneously on 12th week till the end of the study. 
Control groups C0 and C2 were never injected with BOP. C2 was fed 2% curcumin 
throughout the study while as C0 was never fed and curcumin in their control diet. 
Groups that did not receive BOP in any time of the study were injected with equal 
volumes of saline subcutaneously. 
Body weight and food intake was measured weekly throughout the study. 
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Figure 2-1 Brief descriptions about different groups.  
0: 0% curcumin in diet and 
2: 2% curcumin in diet. 
 T0: 0 % curcumin throughout the study. Subcutaneous injection of BOP for first 12 weeks. 
 T2: 2% curcumin in diet after first 12 weeks of subcutaneous injection of BOP. 
 P0: 0% curcumin throughout the study, received BOP injection after first 12 weeks. 
 P2: 2% curcumin throughout the study, received BOP after first 12 weeks. 
 C0: 0% curcumin throughout the study and No BOP 
 C2: 2% curcumin throughout study and No BOP 
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2.5 Urine Collection 
 Hamsters were transferred from regular cages to metabolic cages for 6-8hrs. 
Food was removed to avoid contamination from food pellets in the urine, if any. Urine 
was collected in glass vials precoated with sodium azide (anti-bacterial agent). Sodium 
azide was purchased from ACROS Organics, Thermo Fisher Scientific (NJ). 
 
2.6. Blood and Tissue collection 
 Hamsters were fasted for 8 hrs before sacrificing. All animals were sacrificed by 
decapitation at the end point of study (32 weeks of age). Tissues were harvested and 
weighed. An aliquot was stored in zinc formalin (Richard - Allan Scientific, Kalamazoo, 
MI) at 40C for histological studies and rest of the tissue was snap frozen in liquid 
nitrogen for further assays. Blood was collected in EDTA coated vials and plasma was 
collected immediately by centrifugation at 4500 rpm at 40C for 20 minutes. All the 
techniques were conducted on ice and/or 40C. 
 
2.7 Histology 
 Lung tissue stored in zinc formalin at 40C was subjected to hematoxylin and 
eosin staining. Histology was conducted in histo-pathology lab at Wayne State 
University. Sections of 10-16 micron (12 µm) were cut in cryostat from tissues and 
attached to a No.11U2, 22mm square coverslip. The attached sections were immersed 
in filtered Harris Hematoxylin, acidified for 1 minute, and then rinsed with water until the 
water was clear. Next, the sections were immersed in eosin stain for 1-2 minutes, and 
rinsed with water until it ran clear. Last, the sections were dehydrated in ascending 
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alcohol solutions (50%, 70%, 80%, 95%x2, 100%x2), and cleared with xylene twice. 
The coverslip was mounted onto a labeled glass slide with Permount. 
 
2.8 Immunohistochemistry (Cytokeratin AE1/AE3) 
 Immunohistochemistry staining was performed at Investigative Histopathology 
Laboratory at Michigan State University, under close supervision of a histo-pathologist. 
Specimens were processed, embedded in paraffin and sectioned on a rotary microtome 
at 5 µ’s. Sections were placed on slides coated with 3-aminopropyltriethoxysilane and 
dried at 560C overnight. The slides were subsequently deparaffinized in Xylene and 
hydrated through descending grades of ethyl alcohol to distilled water. Slides were 
placed in Tris Buffered Saline pH 7.5 (TBS) (Scytek) for 5 minutes for pH adjustment. 
Epitope retrieval was performed using 0.03% Pronase E in TBS for 10 minutes at 37ºC 
followed by rinses in  running tap water and several changes of distilled water. Slides 
were placed in Tris Buffered Saline + Tween 20 (TBS+Tw20) (Scytek) for 5 minutes. 
Endogenous peroxidase blocked utilizing – 3% Hydrogen Peroxide / Methanol for 30 
minutes at room temperature followed by rinses in running tap water and several 
changes of distilled water. Slides were then placed in TBS+Tw20 for 5 minutes. 
Following pretreatment standard Avidin-Biotin complex staining steps were performed at 
room temperature on DAKO Autostainer. Slides were rinsed with TBS+Tw20 twice for 2 
minutes between each step of the staining protocol.  After blocking non- specific protein 
with Normal Horse Serum (Vector Laboratories – Burlingame, CA) for 30 minutes; 
sections were incubated with Avidin (Vector Labs) / Biotin (Sigma, St. Louis, MO) 
blocking system for 15 minutes. Mouse Monoclonal Anti-Cytokeratin AE1/AE3 
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(Boehringer Mannheim – Mannheim, Germany) @ 1:300 – 60 minutes in Normal 
Antibody Diluent (NAD) (Scytek –Logan, UT). Biotinylated Horse anti-Mouse (Rat 
Absorbed) IgG H+L (Vector) in NAD diluted 5ug/ml - 30 minutes.  R.T.U. Elite 
Peroxidase Reagent (Vector) - 30 minutes. The slides were developed using Nova Red 
Substrate (Vector) - 15 minutes after which slides were rinsed in distilled water, 
counterstained using Gill 2 Hematoxylin (Thermo Fisher Scientific – Pittsburgh, PA) for 
30 seconds. Dehydrated, cleared through several changes of Xylene and mounted 
using a synthetic mounting media. 
 
2.9 DNA fragmentation (Comet Assay) 
 DNA fragmentation associated to DNA damage in the lung tissue was determined 
by Comet assay kit, purchased from Trevigen Inc (Gaithersburg, MD, USA). Tissue 
samples were removed from liquid nitrogen and chopped into small pieces (1-2mm3). 
After 5 minutes, 1-2 ml of cold 20mM EDTA was added. Avoiding transfer of debris, the 
cell suspension was recovered, cells counted and centrifuged at 1200-1500 rpm for 5-7 
min at 40C. LMAgarose was melted in boiling water for 5min with cap loosened, and left 
in 37°C water bath for at least 20mins to cool.  50 µL  of tissue suspension (1x105 
cells/ml) was combined with 500µL molten LMAragrose at ratio 1: 10 (v/v) in 
microcentrifuge tubes at 37°C and immediately transferr ed (75 µL) onto Comet Slide, 
which were kept at 4°C in dark for 10 minutes or until a 0.5mm clear ring appeared at 
edge of the  Comet Slide area. The slides were pre-chilled in Lysis Solution and left on 
ice for 30 – 60mins, then immersed in Alkaline Solution pH>13, and left for 20 – 60 min 
at room temperature, in dark. Slides were then washed by immersing them in 1X TBE 
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buffer for 5 minutes (X2). Slides were then transferred from 1X TBE buffer to a 
horizontal electrophoresis apparatus, placed flat onto a gel and aligned equidistant from 
the electrodes. Voltage was set at 1Volt/cm for 10minutes. Slides were then rinsed by 
dipping them in 70% ethanol for 5 minutes, then air dried, and 50 µL of diluted SYBR 
Green I was placed onto each circle of dried agarose. Slides were kept in refrigerator for 
5mins, then excess SYBR Green Solution was removed and slides were left to dry 
completely at room temperature in the dark. Slides were viewed by Epifluorescence 
microscope. 
 The length of the tails was quantified using Comet assay IV software (Perceptive 
Instruments, UK). 
 
2.10 NMR Spectroscopy  
2.10.a NMR sample preparation  Urine samples were thawed from -800C and 
equilibrated to room temperature. Once thawed the urine samples were centrifuged for 
10,000 rpm for 5 minutes. Urine was diluted in 1:1 ratio with deuterium oxide (D2O) 
purchased from Cambridge Isotope Inc. (Andover, MA). NMR solvent (in D2O) 
containing 0.5mM 3-(trimethylsilyl) -1 propanesulfonic acid sodium salt (TMSPS) (Sigma 
Aldrich Inc. St. Louis, MO)  and Imidazole (ACROS Organics, Thermo Fisher Scientific 
(NJ) 1mM  were added to the diluted urine sample in 9:1 ratio. Prepared urine sample 
was transferred to NMR tubes (8 inches long and 5 mm in diameter) purchased from 
KONTES glass company (Vineland, NJ). 
2.10.b Proton (1H) NMR Acquisition  NMR spectra were acquired on 500MHz Varian 
spectrophotometer. The free induction decay (FID)s were acquired  using  pulse 
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sequence sw = 6009.6, nt=64, d1=10s, satdly=990.0 ms, pw =9.5 us, mix-hst=100.0 
ms, pw=9.5 us and 4.0 s acquisition. The recommended concentration of imidazole (10 
mM) and urea inherently present in urine were creating dynamic instability between the 
peaks (ADC overflow) in acquiring NMR data so concentration of imidazole was 
reduced to1 mM and urine was diluted to 1:1 ratio. 
2.10.c Spectral processing   All the NMR spectra (FIDs) were processed using 
ACD/1D software (Advanced Chemistry Development, Inc., Toronto, ON, Canada). All 
the FIDs were stacked together as a group and then Fourier transformed as shown in 
figure 13. The whole spectrum was edited from 0.00ppm to 8.75ppm, auto-phased, 
auto-base lined and binned. Intelligent binning/bucketing was used to divide the whole 
spectrum in 1000 bins. Intelligent bucketing allows spectra to be divided in to equal bins 
without dividing a particular peak [33].The spectrum was digitized to a table of common 
integrals and exported as a non-negative value text file. Figures 2-2 to 2-4 depict the 
spectral processing.  
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Figure 2-2 FID files overlaid in ACD Software. 
 
All the FID files acquired from NMR were imported and stacked together in the software for further 
processing. Six fid files are shown in the window for simplification purpose. x-axis represents the time 
domain. 
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Figure 2-3 Processing of FID files in ACD/1D Software. 
The FID files were fourier transformed (FT), auto-phased and baseline corrected. The whole spectra were 
divided into equal 1000 bins. The bins are represented by the red lines in the figure. FT converts 
spectrum from time domain to frequency domain. Now the x-axis represents chemical shifts (ppm). 
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Figure 2-4. Table of common Integral 
 
The spectra were divided into bins and the values were reported as non-negative values. The values 
(ppm) are exported as a text file referenced to as table of common integrals. This is shown as insert in the 
figure. 
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2.11 Multivariate Data Analysis (MVDA) 
The table of common integrals (text file) acquired from ACD/1D software was 
subjected to Multivariate data analysis (Umetrics (Kinnelon, NJ). The data text file is 
imported as excel data sheet. After importing, data is transposed. The first two columns 
of the transposed data set represent the primary and secondary observation. Here 
primary and secondary observations represent the number of animals. Each row 
corresponds to an observation or an entire spectrum or data from one urine sample 
from a specific hamster. The integrals corresponding to spectral region from 4.5 to 6 
ppm were excluded as this region contains water peaks and other aliphatic compound 
with exchangeable protons. Spectral region displaying no peaks, usually beyond 8.75 or 
9.0 ppm (for this study) were also excluded from the data set. After brief editing, 
mathematical models were generated based on predictability (Q2) and variability (R2) in 
the data set. Principle Component Analysis (PCA) and Partial Least Square (PLS) were 
the mathematical algorithms/procedure used to evaluate the data.  PCA is an 
unsupervised mathematical algorithm. It produces a summary showing how the 
observations are related and what are the deviations or similarities in the data set. A 
principal component (PC) is a weighted linear combination of each of the original NMR 
variables so that the original data matrix is compressed into a smaller number of 
variables [34]. The weight given to each variable within a PC describes how influential 
that variable is in relation to the other variables. PCA was used to examine inherent 
clustering and correlations within the data by generating different score plots and 
loading plots. Score plot help to visualize the differences and/or similarities in the data in 
3-dimensinal axis. The parts of spectrum that are responsible for the similarities or 
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variations among the data set were located by loading plot. Loading plot helped to 
identify specific metabolite peak/s that were similar or dissimilar  among the groups 
which was used to identify metabolites.PLS plot helped us to see the correlation 
between the comet assay data (y –axis) and urinary NMR data (x-axis). The data from 
comet assay (DNA damage) were used as y parameter and the urine NMR data was 
used as x parameters. NMR urine data from different time points (weeks) were 
correlated with the comet assay data to see how early we could correlate the two. 
Pareto scaling was used for PCA and for PLS Pareto scaling was conducted for x-axis 
and UV scaling was conducted for y-axis. 
 The following figures (fig.2-5 and 2-6) represent the process of MVDA using 
SIMCA P+ 12.0 software. 
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Figure 2-5. Process of MVDA using SIMCA P+ 12.0 Software. 
Text files obtained from table of common integrals were imported in the software. The files were 
slected in excel format. Here yellow vertical columns are the digitized spectra values and green row is the 
corresponding observation. To further analyze, the data is transposed. 
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Figure 2-6. Labeling of Observations 
 The transposed data was labeled according to the observation. The first two yellow columns were 
the observations labeled as primary ID and secondary ID or vice-versa. Each row represents the digitized 
values for the corresponding urine NMR spectrum. The primary ID represent the particular animal in 
particular group and the secondary ID represents corresponding time point (week of the urine collection) 
for that particular animal followed by NMR data. 
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2.12. Metabolite Identification and Quantification  
  Metabolites responsible for the differences between the groups in NMR data 
were  indentified and  quantified by Chenomx NMR 5.1 suite software purchased from 
CHENOMX INC, (Edmonton, Alberta CA). MVDA (loading plot SIMCA) helped to 
establish the parts of spectra (ppm) that were responsible for similarities or 
dissimilarities between the groups. Focusing on those peaks or parts of spectrum the 
metabolites responsible for the variability in the data set were indentified and quantified 
and exported as data set. The Chenomx software has a processor and profiler. First the 
samples/ FIDs were processed in the processor and then profiled in the new profiler 
window to check for the important metabolites or potential bio-markers. The type (DSS) 
and concentration (0.5 mM) of chemical shift indicator used in the NMR solvent were 
assigned before working with the spectrum. Once the data was fed, the software 
automatically checked for pH. If it fails to check the pH automatically, pH can be set 
manually by adjusting already highlighted peak positions for imidazole in the spectrum 
to our peak positions of imidazole. Creatinine and or difluorotrimethylsilanylphosphonic 
acid (DFTMP) can also be used as pH indicator. After establishing the pH of the 
spectra/ urine samples the spectra were processed. Any line shape distortions created 
by the field inhomogeneity were removed by autophasing, autospline baseline 
correction followed by reference deconvolution. [35-37]. The processed spectra were 
imported into the profiler who has spectral databases for spectra at different magnetic 
strengths and varying pH ranges. The 500 Mhz library was selected to load and 
compare all the potential metabolites with the 500 MHz NMR data acquired. DSS and 
imidazole peaks were matched. Painstakingly, each metabolite and potentially 
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corresponding peaks were matched. Metabolites showing more than one spectral peak 
were divided into different clusters depending on the number of peaks. Each cluster was 
matched to the existing database. The area under the peak, corresponds to the 
concentration of the metabolite. In case of overlapping peaks in a single cluster, clusters 
were matched and re-matched/ re-visited to ensure correct quantification of specific 
metabolites.  After fitting prominent peaks or parts of spectrum, it was important to re-
visit the whole spectrum to make sure that spectral peaks were adequately identified 
and quantified. Metabolites that were significantly important could be traced through 
Kyoto Encyclopedia of Genes and Genomes (KEGG) provided in the software. The 
whole process of quantification is shown briefly in following figures (fig 2-7 to 2-10).  
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Figure  2-7. Chenomx Processor and pH indicator 
 FID files were imported in the processor (chenomx NMR Suite software) for quantification. Before 
the files could be processed pH determination was conducted either automatically by the processor or 
manullay depending on the sample. In the pH editor window, the pH of the sample could be determined 
by already existing peaks of three pH indicators in the database. Imidazole was added as pH indicator, 
which is represented by blues vertical lines in the spectrum.  
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Fig 2-8. Processing the FID file (phasing, baseline correction and reference deconvolution) 
 The spectrum was auto phased and auto- spline baseline corrected. Auto-spline baseline 
correction could help to clean the noise better than auto-baseline correction and . Reference 
deconvolution was conducted to enhance the spectrum quality by removing the line distortion caused by 
the field inhomogeneity. The file is processed and exported to profiler for quantification. 
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Figure 2-9.  Quantification of metabolites (Profiler) 
 The processed file was imported to profiler (Chenomx NMR Suite 5.1) for quantification of peaks. 
Before quantifying any peaks, Chenomx magnet library was selected. The Chenomx library has libraries 
for different magnets from 400 Mhz to 800 MHz and pH range can be selected from (pH4-9 or pH 6-8). 
Chenomx 500 MHz (pH 6-8) was selected since all the FIDs were acquired on 500 MHz and pH ranged 
from 7 to 8.3. The NMR peaks/spectrum of acquired file (red peaks) was compared and matched to the 
NMR spectrum of data-base (blue peaks). 
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Figure 2-10. Pathway interpretation 
The matched peaks were quantified and exported to excel. The quantified metabolites were 
plotted against samples of different groups. The metabolites that were significantly different (p<0.05) were 
further investigated for pathway interpretation. KEGG (Kyoto Encyclopedia of Genes and Genomes) an 
online library supported by software was used to interpret that pathways. Software was used to visualize 
quick structure of particular metabolites. 
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2.13. Validation    
The quantified Chenomx metabolites data set were analyzed and validated with 
the help of SIMCA P+ 12.0 software. MVDA was conducted on the Chenomx data set to 
see if the corresponding metabolites responsible for variability will fall in the same group 
as proven by Chenomx.  PCA Score plots and loading plots were plotted to validate the 
data from chenomx. 
 
2.14. Statistical analysis  
 Apart from using SIMCA P+ for MVDA, the other statistical data were analyzed 
and obtained either by using Microsoft excel (t-test) or one-way-analysis of variance 
(ANOVA), using SPSS (version 16) or ezanova Software. The p value less than 0.05 
were considered statistically significant. 
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Chapter 3: Results 
Specific Aim 1: 
 The objective of this aim was to determine anti cancer effect of curcumin on lung 
cancer in cancer induced animal model. Cancer was induced  by injecting BOP and 2% 
curcumin diet was included in respective groups as described in chapter 2 (methods). 
The number of animals (n) in group T0, T2, P0, P2 were 10 each and for group C0 and 
C2 n = 6. 
 
Diet Intake: 
 All the groups were fed food and water ad libitum. Diet intake was measured 
weekly.  There was no significant difference in diet intake between all the groups 
throughout the study (Figure 3-1). 
 
Mean Body Weight 
 All the hamsters were weighed weekly. When compared towards the end of the 
study, the mean body weight was significantly different between the cancer induced 
treatment group (T0, T2) and control (C0, C2) and prevention (P2) group. There was no 
significance difference between the mean body weights of control and prevention group 
and between treatment and prevention group (P0) (figure 3-2). 
 
Incidence of lung cancer 
 Lung cancer was induced by subcutaneous injection of a chemical carcinogen 
BOP (10mg/kg body weight) in T0 and T2. Controls (C0 and C2) were not given any 
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carcinogen so there was no cancer induction. Inspite of BOP injections for 12 weeks 
cancer was not observed in the prevention group.The incidence of lung cancer in 
Treatment group T0 was 45.5%, whereas in T2 only 11.1%, reaching significance at 
90% confidence level (propotion test, statistical analysis p< 0.1) (figure 3-3). 
 
Hamster survival rate 
At the end of study hamster survival rate was calculated. All the hamsters in 
control group (C0, C2) and prevention group (P0, P2) survived. There was 100 % 
survival rate for prevention and control groups. There was significant difference 
between the treatment group, prevention and control group. There was even significant 
difference in the rate of survival among T0 and T2, 27.3% and 77.7% respectively 
(figure 3-4).  
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Figure 3-1 Mean Diet Intake 
All the groups were fed food and water ad libitum. Diet intake was measured weekly.  There was 
no significant difference (p > 0.05) in diet intake between all the groups throughout the study.  
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Figure 3-2 Mean Body Weight. 
 Even though the animals were fed ad libitum there were still significant differences between the 
mean body weights of different groups. There was no significant difference between the prevention and 
control groups but there was significant difference in mean body weight of treatment (T0, T2) and P2 and 
control group. There was no significant difference between treatment (T0, T2) and prevention (P0). T0 
and T2 significantly lower compared P2, C0 and C2 (*p<0.05)  
 
 
  
 
 
 
 
* 
* 
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Figure 3-3 Incidence of Lung Cancer. 
 The inicidence of lung cancer was detected by histology slides. There was no cancer in controls 
C0 and C2 as they were not given any carcinogen (BOP). The prevention group was injected with 
carcinogen too after week 12 of study but there was no detection of lung cancer. The only group that 
showed incidence of lung cancer was treatment and the incidence of lung cancer in Treatment group T0 
was 45.5%, whereas in T2 only 11.1%, reaching significance at 90% confidence level (p< 0.1) (Proportion 
test statistical analysis)  
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Figure 3-4. Survival rate 
 Hamster survival rate was calculated at the end of the study. There was no death of any animal in 
prevention (P0, P2) or control (C0, C2) groups. In the treatment group cancer was induced so hamsters 
started to die as the disease progressed.  There was significant difference (a vs. b * p < 0.01) between 
the survival rate among T0 and prevention (P0, P2) and control (C0, C2) and even among T0 and T2. 
The survival rate for prevention (P0, P2) and control (C0, C2) was 100% and for T0 and T2 it was 27.3% 
and 77.7% respectively. Groups with same letters are significantly different. 
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Histology: 
 Cancer incidence was confirmed by histological studies. Hematoxlyin and eosin 
(H &E) staining was conducted to confirm the cancer induced by BOP as well as the 
anti-cancer and anti-inflammatory effects of curcumin. Hematoxylin stains basophilic 
structures (DNA, RNA). Eosin stains acidophilic/eosinophillic structures (proteins, 
RBCs). H&E staining helps to distinguish between normal and atypical architecture. The 
slides were examined and studied by an expert and experienced histopathologist.  
The slides from different groups showed significant differences in tissue 
architecture. Control groups showed no lesions or atypical cell growth. The appearance 
was like a thin lace, because of the presence of thin walled alveoli. There was no 
significant amount of inflammation, no fibrosis or consolidation of the lungs as 
compared to other groups. The controls had healthy normal lungs (figure 3-5 and 3-6). 
 In the prevention group differences were noted among the cell architecture of P0  
and P2 groups. In P0 group there was some patchy consolidation of the lungs. There 
was infiltration of macrophages and plasma cells, indicating severe inflammation. There 
were few lesions and patchy interstitial fibrosis. The lungs also showed vascular and 
peri-vascualr inflammation (figure 3-7 and 3-8).  On the other hand P2 showed a low 
level of inflammation in an overall normal lung (figure 3-9). Both P0 and P2 showed 
signs of no obvious tumor. Both group P0 and P2 lung slides stained negative for 
tumors. 
 In the treatment groups there was maximum variabilityin the lung tissue 
architecture. T0 had atypical lung architecture. There was parenchymal hemorrhage 
and edema. The epithelial cells showed lung pleomorphism with focal destruction of 
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alveoli focally. Some of the bronchial epithelial cells are in mitosis. The cells have bigger 
nuclei than normal. Higher nuclear to cytoplasm ratio is indicative of tumor cells. There 
were dysplastic changes and cluster of cells stained for well differentiated tumor. 
Dysplastic bronchial lining is  indicative of pre-malignancy. In few of the slides there was 
severe bronchial pneumonia with atypical cells. There was pappilary 
proliferation/hyperplasia. There was squamous metaplasia, this can be just a reactive 
reaction (figure 3-10). Group T2 did not show unequivocal tumor, although there were 
few areas of suspicion which were later ruled out by immuno-histochemistry. These  
lungs were not in healthy condition as compared to controls.  There were few atypical 
multinucleated cells which could not be attributed to reactive changes due to infection. 
Some slides had capillary proliferation and advanced inflammation (figure 3-11). In 
treatment group, group T0 stained positive for tumor and group T2 stained negative but 
there were some suspicions about group T2 which would be confirmed by immune-
histochemistry. 
 Extra-care was taken while studying or analyzing the histological slides, to avoid 
some of the pitfalls (staining of unwanted cells). Information about the morphology of 
cell architecture helps to distinguish between the real positive staining and pitfalls. 
Some of the common pitfalls encountered were staining of plasma cells, binucleation 
and other reactive (inflammatory) changes might also mislead the results.  
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Figure 3-5: H & E Staining of Control Group (10X magnification) 
 The figure shows H & E stained normal healthy lung tissue of Golden Syrian hamster under 10X 
magnification. The labeling ‘A’ on the figure shows thin walled normal alveolar spaces. The whole tissue 
is intact with normal preserved architecture. There is no condensation of stroma and no atypical cells are 
noted. 
 
 
 
 
 
 
 
A 
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Figure 3-6: H & E Staining of Control Group (40X magnification) 
 The figure shows H & E stained normal healthy lung tissue of Golden Syrian hamster under 40X 
magnification. The alveoli are thin walled with a lace like architecture. There is no collapse or stromal 
condensation. The alveoli have very well defined septa. 
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Figure 3-7. H & E stained Lung Prevention (P0) group (10X magnification) 
 The figure depicts the H & E stained lung tissue of prevention (P0) group under 10X 
magnification. The tissue has very few air vacuoles. This is not a healthy lung and there is focal suspicion 
about the tumor which cannot be confirmed with H & E.  A: shows that there is fibrosis. The lungs showed 
less compliance. B: shows the atypical cells and inflammation of the vessels and bronchioles. C: 
illustrates the consolidation of the lung. The stroma is busy and condensed. There are no clear thin wall 
alveoli visible. 
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Figure 3-8. H & E stained Lung Prevention (P0) group (40X magnification) 
 The figure depicts the H & E stained lung tissue of prevention (P0) group under 40X 
magnification. The label A:  shows inflammation of vessel (vasculites) and the label B: shows 
parenchymal hemorrhage, inflammation and busy stroma. 
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Figure 3-9. H & E stained lung tissue, prevention group (P2). (10X magnification) 
 The figure shows H & E stained lung tissue for the prevention group (P2) under 10X 
magnification. The label A: shows some consolidation and hemorrhage, B: shows a clean section of blood 
vessel. C: shows normal thin lined alveoli with adequate architecture for exchange of gases. The tissue 
was healthy but not as healthy as control. Some consolidated and hemorrhagic areas were seen but 
there were no signs of tumor. 
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Figure 3-10. H & E Stained Lung tissue, T0 group (40X magnification) 
 Figure shows H & E stained lung tissue for treatment (T0) group under 40X magnification. The 
tissue is highly consolidated. There is almost no compliance. Alveoli were lined with atypical cells. The 
label A: shows atypical cells with dark stained nuclei. Lots of cells had higher nuclear to cytoplasm ratio 
which is indicative of tumor. B: shows a big giant atypical tumor cell. C: shows consolidated stroma. D: 
shows parenchymal hemorrhage. 
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Figure 3-11. H& E stained lung tissue, treatment group T2 (40X magnification) 
 Figure shows H & E staining of lung tissue for treatment group T2 under 40X magnification. The 
tissue showed chronic inflammation. The figure shows A: lymphocytes, B: eosinophils, C: neutrophils, D: 
plasma cells and E: macrophages. The tissue shows parenchymal hemorrhage, capillary inflammation 
and proliferation but no signs of tumor. Tissue stroma is consolidated. 
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 The H & E staining differentiated between the normal healthy tissue and atypical 
tissue. To confirm and validate the results immuno-histochemistry was conducted. 
Immuno-histochemistry would differentiate between the atypical suspicious cells and 
cancerous atypical cells.  
 
Immunohistochemistry: 
Immunohistochemistry was conducted only for the groups (T0, T2 and P0) that 
showed atypical cells and suspicious tissue architecture from H & E staining. 
Cytokeratin (CK) staining was used for immune-staining. Keratins are a group of water 
insoluble proteins which form cytoskeletal complex in epidermis and most other 
epithelial cells. Pancytokeratin AE1/AE3 was used. It is a mixture of two different clones 
of anti-cytokeratin monoclonal antibodies, AE1 and AE3. 
The results showed that only group T0 stained positive for the stain (AE1/AE3) 
(figure 3-12). Cells in mitosis were also seen and stained (figure 3-13) and giant tumor 
cells were also confirmed (figure 3-14). Some other cells also showed falsely stained 
pattern (e.g. plasma cells were stained too which is not the real effect and might lead to 
incorrect interpretation of the slides). All these cells were carefully scrutinized for the 
pitfalls.  
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Figure 3-12.  Positive immuno-stain for CK AE1/AE3 (10X magnification) 
 The figure shows positive immuno-staining for T0 group under 10X magnification. The slide was 
confirmed for adenocarcinoma.  
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Figure 3-13. Cells depicting Mitosis (60X magnification) 
 The figure shows positive immune staining for CK AE1/AE3. The lung epithelium showed cells in 
mitosis which is an indicative of rapid cell growth, increased nuclear to cytoplasmic ratio which indicative 
of tumor cells. 
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Figure 3-14. Lung tissue immuno-stained Ck AE1/AE3 (40X magnification) 
 The figure shows two giant single pre-neoplastic cells stained positive for the stain. Few other 
cells stained positive too but those were plasma cell, which is not of lung origin but indicative of 
inflammation or infection. These cells should not be misinterpreted as tumor cells (pitfall). 
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DNA Damage (comet assay) 
 Lung cancer was induced by chemical carcinogen BOP which is known to cause 
single strand breaks. DNA damage was estimated by comet assay. It is used as a 
qualitative test for DNA damage in single cell. Cells were harvested from lung tissue. 
 The results of DNA damage were calculated by measuring the tail length (um) for 
each cell (figure 3-15 to 3-17). Tail length is directly proportional to DNA damage. The 
length of the tails was measured using Comet assay IV software (Perceptive 
Instruments, UK). There was significant difference (* p< 0.05) in DNA damage between 
treatment group (T0, T2) and control (C0, C2) group. There was significant difference (* 
p< 0.05) among treatment group itself (T0 and T2) indicating effect of curcumin (figure 
3-18). There was no significant difference among control group (C0 and C2).  
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Figure 3-15. DNA Damage for group T0 
 The figure shows lung cells with the DNA damage. The length of tail is directly proportional to the 
DNA damage. 
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Figure 3-16 DNA Damage for group T2. 
 The figure shows lung cells with the DNA damage. There are few cells that have tails and fewer 
with smaller tail or no tail. Group T2 has less DNA damage than group T0 as shown in the figure. 
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Figure 3-16 DNA Damage for Control group. 
 The figure shows lung cells with the DNA damage. There was significantly less DNA damage in 
the control group as seen in the figure. All the cells are round than elongated as seen previously in 
treatment group T0 and T2. 
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Figure 3-18 Comet Assay tail lengths.  
 Figure illustrates the difference between the comet tail lengths between the groups. There was 
significant difference between the control (C0, C2) and T2 and T0. There was significant difference 
among the treatment group T0 and T2. The tail lengths were calculated by Comet assay IV software.T0 
and T2 were significantly higher (p < 0.05) than controls indicating more DNA damage. T0 was even 
significantly higher than T2 (p<0.05). C0 &C2 were not significant (P>0.05). Groups with same lettes are 
significantly different. 
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Summary of specific aim 1: 
 
Cancer was successfully induced in Golden Syrain hamster animal model. 
Histology studies revealed prevalence of cancer in the group that was injected with BOP 
and showed curcumin could alleviate the condition. Comet assay showed significant 
DNA fragmenatation in the T0 and T2 as compared to controls and there was significant 
difference among the treatment group itself (T0 and T2).  
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Specific Aim 2 
 The objective of this aim was to study change in urinary metabolomic profile with 
cancer progression using 1D proton NMR. Urine was collected weekly and stored at -
800C till further use. The sample was prepared and NMR FID files were acquired using 
500 MHz Magnet. The files were processed in ADC 1D NMR software and MVDA was 
conducted using SIMCA P+ software. 
 
NMR Data Processing: 
 Acquired NMR FID files were fed to the ADC software and processed. The files 
were Fourier transformed, phased, baseline corrected and binned (3-19 and 3-20). The 
whole spectrum was transformed to table of common integral and exported as non-
negative integer values as text file. 
 
Multivariate Data Analysis: 
 The huge data files acquired from NMR were ready for MVDA analysis after 
processing. PCA and PLS showed significant differences between the groups and 
between the same groups at different time points (weeks). 
PCA 
 The effect of BOP and curcumin were clearly shown by PCA plots. 
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Effect of BOP:   
 First PCA was conducted on week 11 samples for T0 and T2. There was no 
significant difference since both T0 and T2 at week 11 are same (figure 3-21). Both 
groups were injected BOP till week 12 and after week 12, curcumin was added in the 
diet of group T2. The figure shows both T0 and T2 randomly arranged in the eclipse. 
There is no pattern between the groups. The effect of BOP is similar in both groups. 
 PCA was conducted for week 16th for again same groups (T0 and T2). There was 
a pattern of separation between the two groups but there was no significant separation 
(figure 3-22). The T2 group has 2% curcumin in diet and T0 has normal purified casein 
diet.  The effect of BOP is more than the effect of curcumin at this point of time but there 
is a trend. 
 To see the effect of effect of BOP on hamsters, group T0 was compared for week 
0 (baseline) and week final. The PCA plot showed clear differences between the two 
time points of same group (figure 3-25). The urinary NMR profile of hamsters was more 
intact/close to each for week final than week 0 which indicates that at week 0 there was 
more inter animal difference but as time proceeded and hamsters developed cancer, all 
the animals had somewhat similar profile. Loading plot showed the parts of spectrum 
area (peaks for the metabolites) that might be responsible for cancer development and 
inter-hamster differences (figure 3-26). 
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Effect of Curcumin : 
The PCA for week final (24th week) showed clear separation between the groups. 
The separation was clear and significant (figure 3-23). The effect of curcumin could be 
seen from the PCA plots. The only difference between T0 and T2 is 2% curcumin in 
diet. From the PCA plot we could say curcumin changed the metabolic profile of T2 
group.  The loading plot (figure 3-24) showed the peaks /areas of the NMR spectrum 
that were responsible for the difference between the two groups e.g. the peaks around 
1.16, 1.29, 4.34 etc. ppm were responsible for T0 to be different from T2 and likewise 
3.23-3.25, 3.59- 3.60 etc. ppm peaks around this were responsible for T2 to be different 
from T0 etc, (rest discussed in the figure description).  This could help in detection of 
peaks or metabolites that are different in cancer (T0) group and peaks responsible for 
curcumin intervention. It also showed the common peaks between the two groups.  
 PCA was conducted between control group C0 and C2 final week to see the 
effect of curcumin on the urinary profile (figure 3-27). The C0 group had more intact 
urinary NMR profile than group C2.   
 Finally, group T0 was compared with C0. Comparison was conducted between 
various time point (weeks) but the final week showed the most significance and 
separation. PCA for T0 and C0 week final showed the most separation (figure 3-28) and 
loading plot showed the parts of spectrum that is responsible for separation (figure 3-
29). The metabolite peaks or parts of the spectrum that are responsible for the 
separation of group T0 from group C0 could be the metabolites that are responsible for 
the cancer and could eventually be potential early biomarkers after further analysis and 
validation. 
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PLS 
 NMR urinary profile for group T0 and T2 (week final) was correlated with DNA 
damage data (comet analysis). There was high correlation (R2 = 0.68) between the DNA 
damage in lungs and urinary profile of hamsters (figure 3-30). These results implicate 
that there are some metabolites in the urine samples that are correlating with DNA 
damage in the lung tissue. 
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Figure 3-19 Fourier transformed unprocessed NMR spectra 
 The FID file in time domain is Fourier transformed to spectra in frequency domain. The spectrum 
is not phased, baseline corrected and edited. This unprocessed spectrum has parts which are not 
required for analyzing the data e.g. any part less than 0ppm or more than 8.75 is not required so it is 
needed to be edited. Since the spectrum has no signals upfield of the 0 ppm or downfield of 8.75 ppm, it 
is not required for metabolite identification or quantification and hence needs to be removed. 
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Figure 3-20  Fourier transformed (Processed NMR Spectrum) 
 The spectrum is phased, baseline corrected and edited. This spectrum is ready for binning and 
analysis. 
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Figure 3-21 PCA Score Plot for urinary NMR Spectra obtained from hamsters in group T0 (0% 
curcumin) and T2 (2% curcumin) at week 11 of the study. 
 The PCA plot shows that the metabolomic profile obtained from T0 and T2 is similar. Both the 
groups are same at this point of time. The observation labeled in red are T0 and others are T2. T0 and T2 
both were injected with BOP and were on same diet for 11 weeks. The eclipse represents the 95th 
percentile of confidence interval and hence anything in the eclipse is considered significant. Any score 
outside the eclipse is an outlier and may be removed from the analysis. 
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Figure 3-22 PCA Score Plot for urinary NMR Spectra obtained from hamsters in group T0 (0% 
curcumin) and T2 (2% curcumin) at week 16 of the study. 
 This is the PCA score plot between group T0 and T2 at week 16. There is still no evident 
separation but there is a pattern. The observations are less random as compared to week 11. The only 
difference between T0 and T2 is that curcumin is added to diet of T2 and T0 is on same control diet 
throughout the study. The profile represents the effect of BOP injections uptil week 12 and the effect of 
2% curcumin in the diet of group T2 while T0 is on 0% curcumin diet. At this point the effect of the 
carcinogen is stronger then the effect of diet differences as represented by an overlap between the score 
points from groups T0 and T2. 
 
 
 
 
-20
-18
-16
-14
-12
-10
-8 
-6 
-4 
-2 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
-28 -26 -24 -22 -20 -18 -16 -14 -12 -10 -8 -6 -4 -2 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
t[2]
t[1]
T0 vs T2 wk 16
R2X[1] = 0.490205            R2X[2] = 0.244183            Ellipse: Hotelling T2 (0.95) 
T0
T2
T0 T0
T0
T0
T0
T0
T0
T2
T2
T2
T2
T2
T2
T2 
T2
  
 
90
 
Figure 3-23 PCA Score Plot for urinary NMR Spectra obtained from hamsters in group T0 (0% 
curcumin) and T2 (2% curcumin) at week 23 (final) of the study. 
 This the PCA plot between group T0 and T2 for final week of urine samples. There is significant 
separation as can be seen from the figure. The observations in the oval are from group T0 at final week. 
The NMR urinary profiles of observations in the group T0 are closely related to each other as compared 
to the observations in the group T2. Group T2 has curcumin in their diet so the urinary profile might 
change depending on curcumin metabolism which could be a result of inter-hamster differences. When 
other weeks were compared, final week showed the best separation. In comparison to figure 3-22, PCA 
plot at week 16, we conclude that by week 23, the effect of curcumin in the diet of T2 group (2% 
curcumin) is making a considerable effect to cancer progression induced by BOP. 
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Figure 3-24 PCA Loading Plot for urinary NMR Spectra obtained from hamsters in group T0 (0% 
curcumin) and T2 (2% curcumin) at week 23 (final) of the study.  
 This figure is the corresponding loading plot for the figure 3-23. This loading plot gives information 
about the parts of spectrum that are different and common between the two groups. The dense, dark area 
in the center represents the metabolites that are common to both the groups. This plot signifies parts of 
the spectrum that are responsible for significant separation between the T0 and T2 group e.g. here in this 
plot 4.33 – 4.34 , 7.16 - 7.17, 1.26 ppm etc. (encircled in red circle) is the part of the spectrum that is 
responsible for the separation of T0 from T2  and likewise 3.23 – 3.25,3.59-360 ppm etc (encircled in 
blue) for T2.  
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Figure 3-25 PCA Score Plot for urinary NMR Spectra obtained from hamsters in group T0 (0% 
curcumin) week 0 and T0 (0% curcumin) at week 23 (final) of the study. 
 The figure shows the PCA plot for group T0 between week 0 and week final. There is clear 
separation as seen from the figure between the two time points for the same group T0. The observations 
in the blue circle are from the week final and they are more closely together than the observations for 
week 0. The animals at the final week had developed cancer so their metabolic profile were similar to 
each other as compared to animals or observation at week 0. Hence, the observations at week final is 
more closely together than week 0. 
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Figure 3-26 Loading plot for group T0 between different time points (week 0 and week final) 
 The figure shows the parts of the spectrum that are responsible for the separation between the 
week 0 and week final NMR urine profiles of group T0.  The known spectrum area would show the 
peaks/metabolites responsible for the separation which would indicate metabolites responsible for cancer. 
The part of the spectra that are in red circle are the metabolites different in T0 Week final and peaks 
around these ppm would be the metabolites responsible for cancer and the ppm that are in blue circle are 
the peaks that are different in normal hamsters at week final. 
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Figure 3-27 PCA Score Plot for urinary NMR Spectra obtained from hamsters in group C0 (0% 
curcumin) and C2 (2% curcumin) at week 23 (final) of the study. 
 The figure shows the differences between the observations of group C0 and C2 at week final. 
Group C2 (represented by yellow) was given curcumin in the diet throughout the study and group C0 was 
given normal control diet. The urinary NMR profiles were compared at week final. There are again 
differences in metabolizing curcumin (C2) as seen from the figure (inter-hamster differences). The PCA 
shows urinary NMR profiles are similar for group C0 to each other than the observations of group C2. 
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Figure 3-28 PCA Score Plot for urinary NMR Spectra obtained from hamsters in group T0 and C0 
(0% curcumin) at week 23 (final) of the study. 
 The figure shows significant separation on PCA plot for group T0 and group C0 for final week or 
urinary NMR profiles. At week final group T0 had developed lung cancer and group C0 is normal and 
healthy. These profiles could be hence related to urinary NMR profiles of cancer and healthy. Again seen 
here the observations in group T0 are more closely similar to each other than the observations in C0 
group. 
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Figure 3-29 PCA Loading Plot for urinary NMR Spectra obtained from hamsters in group T0  and 
C0 (0% curcumin) at week 23 (final) of the study. 
 The figure shows the loading plot for week final between group T0 and C0. As established earlier 
in the corresponding PCA plot that the two separate profiles could be related to healthy and lung cancer, 
the loading plot could give lots of significant information e.g. the peaks around 3.53-3.54 could be the 
metabolites responsible for the lung cancer in hamsters and thus separates out itself from the healthy 
hamster population. This information would help to scrutinize the NMR spectrum quicker than the usual. 
As discussed earlier the metabolite peaks that are in red circle could be probable bio-markers for the lung 
cancer as these are the major metabolites that are responsible for the differences between the cancer 
group (T0) and control (C0) group. 
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 Figure 3-30 Partial Least Square (PLS) plot. 
 The figure shows PLS correlation plot between the DNA damage data estimated by comet assay 
in lung tissue (y-axis) and urinary NMR profile of treatment group (T0, T2) x-axis for final week.The figure 
shows good correlation DNA damage and the metabolites in the urinary profile. This shows that some 
metabolites in urine can predict or correlate with the DNA damage in the lung tissue.  
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Summary of specific aim 2 
With the help of NMR technique and use of SIMCA P+ (PCA score plot) 
differences were observed between the urinary profiles of treatment group (T0, T2) and 
control group (C0, C2). With the help of SIMCA P+ (PCA loading Plot) we could locate 
the peaks/parts of the spectrum responsible for the variability between the groups. Parts 
of the spectrum were recognized that could be potential biomarkers for the lung cancer 
(loading PCA plot) figure (3-23, 3-24).Comet data (Y axis ) and Urinary NMR data (x-
axis) correlated with each other (PLS plot ) figure (3-30) 
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Specific Aim 3 
 The main objective of this aim was to determine potential early biomarkers 
for lung cancer. The FID NMR files were imported to Chenomx NMR Suit 5.1 to 
determine the peaks/metabolites that were responsible for differences between 
group T0 (cancer induced) and group C0 (control). The significant metabolites 
were traced back to the biochemical pathways they are involved in so to interpret 
the metabolomic profile of group T0 during lung cancer . 
 
Metabolite Identification, Quantification and Pathway Interpretation  
 Metabolite peaks were identified and matched to the  existing database of 
292 urine metabolites.  Out of 292 metabolites 68 metabolites were found to be 
different between the lung cancer induced group (T0) and the control group (C0) 
(table 3-1). Statistical analysis t-test was used to see whether or not there was a 
significant difference in concentration of these quantified 68 metabolites.  Out of 
68 metabolites, 27 metabolites were found to be significantly different between 
the two groups T0 and C0 (table 3-2). The urine samples were diluted 1:1 while 
making NMR samples so all the quantitative values that were achieved from 
chenomx where multiplied by a factor of 2  and plotted as a bar graph. This gives 
the actual concentration (uM) values of metabolites in the urine sample. The 
metabolites that were found significantly different between the two groups were 
traced back to the biochemical pathway/s that they might be involved in through 
KEGG database and literature survey. After analyzing  for all the significantly 
different metabolites an overall picture of the pathway/s was plotted and almost 
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all the metabolites that were significantly different were directly related or closely  
involved with each other. The results showed (most of them) that if a metabolite 
was higher in concentration during cancer progression curcumin in the diet 
reduced it e.g. Figure 3-31 shows that the concentration of 2-oxobutyrate (2-OB) 
was increased in group T0 and T2 indicating  increase in cancer progression. 
However, its concentration was significantly decreased in T2 (after 2% curcumin 
diet was added to the diet) showing the effect of curcumin on 2-OB or its 
particular pathway. Although there was no significant reduction (except in few 
cases) in the levels but there was a trend seen. The figures (3-31 to 3- 60) shows 
the metabolites that were significantly different in cancer induced group (T0) and 
control group (C0) and the pathways they are involved.  All these metabolites 
could serve as potential early bio-markers for lung cancer. 
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Table 3-1  Urinary Metabolites Profiled from Chenomx Database -- Non significantly 
different in concentration between T0 and C0 groups 
 The table 3-1 shows the metabolites that were quantitated in the chenomx database. This 
table shows metabolites whose concentration were not significantly ( p > 0.05) different from 
eachother. Although there were some of the metabolites that were reaching significance or 
showing trend towards the significance (bold). Out of 68 profiled metabolites 41 were not 
significantly different in concentration in the 2 groups as shown in the table. The metabolites in 
the table are arranged in alphabetical order. 
 
 
 
Metabolites  Profiled  from Chenomx not signficantly different 
2-Phosphoglcerate Citrate Kynurenine  
Acetaldehyde Creatine  Lysine 
Acetaminophen Creatine phosphate Malate  
Acetate Creatinine  Malonate  
Acetoacetate  Dimethylamine  Methylmalonate  
Acetone Ethylene glycol Methylsuccinate  
Acetylsalicylate Formate  Phenylacetate  
Adipate  Glutamate Phenylacetylglycine  
Allantoin  Glutathione Phenylalanine 
Alloisoleucine  Glycerate  S-Sulfocysteine 
Arginine  Guanidoacetate Succinylacetone  
Asparagine  Histidine Tartrate 
Aspartate Homoserine Threonate 
Benzoate Indole-3-acetate  
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Table 3-2  Urinary Metabolites Quantified  from Chenomx whose concentration were 
significantly different in groups T0 and C0  
 The table 3-2 shows the 27 metabolites out of 68 profiled metabolites that showed 
significant ( p < 0.05) differences between the cancer induced group (T0) and control group (C0). 
All the metabolites are arranged in alphabetically order in the table. These metabolites were later 
traced back to their biochemical pathways. Almost all the metabolites were higher in the cancer 
induced group(T0) than the control group (C0) except for the metabolite glycolate which showed 
higher concentration in control group (C0). 
Profiled Significantly different metabolites from Chenomx Database  
 
2-Methylglutarate Glycylproline 
2-Oxobutyrate Histamine 
2-Oxoglutarate Lactate 
3-Hydroxybutyrate Leucine 
5-Hydroxylysine Proline 
Acetamide Pyruvate 
Alanine Sarcosine 
Betaine Serine 
Choline Serotonin 
Fumarate Succinate 
Glutamine Taurine 
Glycine Threonine 
Glycerol Trimethylamine N-oxide 
Glycolate  
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Figure 3-31 Urinary 2- Oxobutyrate (2-OB) concentration, comparison between different groups. 
 The figure shows the differences in the concentrations (uM) of 2-oxobutyrate. The concentration 
is in micro molar. As seen from the figure there is significant difference between control (C0)  week final 
and  treatment (T0) week final (p< 0.0058) and there is significant difference between group T0 and T2 
week final (p<0.0308) too. The first column in the figure shows concentration of 2-OB at week 10. At week 
10 group T0 and T2 were under identical conditions i.e. no curcumin was provided in the food. And as T0 
progress towards week final the concentration of 2-OB increases too but when curcumin is given to T2 
after week 12 there was a significant reduction in the concentration of 2-OB. The curcumin in the diet 
tends to bring the cancer induced group towards the profile of control (C0) group. This trend was seen 
throughout the study with other metabolites too although not all were significantly different. There was 
significant difference (p<0.01) between T0 week 10 and control week final (C0) but since T0 week 10 and 
C0 week final are at different ages  or time point, significance might not be considered. This is to show 
the trend in change in specific metabolite with cancer progression and curcumin interaction. Colums with 
same letter are significantly different. 
 
 
 
 
 
 
 
T0 vs C0 p = 0.0058 
T0 vs T2 p = 0.0308  
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Figure 3-32 Comparison of urinary Lactate concentration between groups T0 and C0  at week final. 
 The figure shows the concentration of lactate between cancer induced group (T0) and control 
group (C0). There was significant difference (p<0.05)  between the two groups. Lactate is the end product 
of fermentation procees formed from pyruvate during normal exercise and metabolism 
 
 
 
 
 
 
 
 
 
T0 vs C0 p = 0.0186 
  
 
105
 
 
Figure 3-33  Comparison of urinary Pyruvate concentration between T0 and C0 week final. 
 As seen in the figure cnacer induced group (T0) has significantly (p< 0.05) higher levels of lactate 
than control group (C0).Pyruavte is the end produt of glycolysis. 
 
 
 
 
 
 
 
 
 
 
 
 
T0 vs C0 p = 0.0128 
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Figure 3-34  Comparison of urinary Fumarate concentration between T0 and C0 week final. 
 The figure shows that the concentration of fumerate which is a KREB’s /TCA cycle product, is 
significantly (p<0.05) higher in cancer induced group T0 than the control group C0. 
 
 
 
 
 
 
 
T0 vs C0  p = 
0.024 
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Figure 3-35 Comparison of urinary 2-Oxoglutarate (2-OG) concentration between T0, T2  and C0 
week final.  
 The figure shows the comparison between the concentration of 2-OG between cancer induced 
group (T0), cancer induced + curcumin provided group (T2) and control group (C0). There were 
significant differences between then groups. T0 was significantly higher (p < 0.05) than control C0 and 
group T2 were also significantly higher ( p< 0.05) than control C0. There was no significant difference 
between the T0 and T2 group but there is a trend of 2-OG levels being less in curcumin provided group. 
Curcumin tends to alleviate the condition. 2-OG also known as alpha keto-glutarate is an intermediate 
compound in TCA cycle. Colums in letters are significantly different. 
 
 
 
 
 
 
 
 
T0 vs C0 (a*) p = 
0.025 
T2 vs C0 (b*) p = 
0.020 
a b  
a 
b 
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Figure 3-36 Comparison of urinary Succinate concentration between  group T0, and C0 week final.  
 The figure shows succinate which is a TCA intermediate metabolite is significantly higher 
(*p<0.05) in caner induced group (T0) as compared to control group (C0). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T0 vs C0 p = 0.0092 
* 
* 
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 The metabolites as seen from figure 3-31 to 3-36 have common metabolic 
pathway as compread from KEGG and literature survey. All the metabolites are realted 
to energy/glucose metabolism. Results show all the metabolites quantified either belong 
to glycolysis or TCA cycle directly or indirectly and all these metabolites are significantly 
higher in lung cancer induced group (T0) when compared to control group (C0). With all 
this information, a preliminary metabolic pathway was drawn to see at what step of the 
energy metabolism these pathways were affected (figure 3-37 and figure 3-38). It was 
concluded from all these results that the lung cancer induced group (T0) are more 
active or agressive metabolically than control group (C0). This is consistent with the fact 
that as cells are growing faster, there is a demand for more energy so pyruvate gets 
converted to lactate for faster energy. The pyruvate is replenished by glucogenic amino 
acids while glycolysis and TCA intermediates are replenished by anaplerotic reactions.   
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Figure 3-37 TCA cycle (KEGG) 
 The red arrows along the metabolites show  pyruvate, 2-OG, Succinate, and fumarate were seen 
significantly higher in cancer induced group (T0). The pathway does not show 2-OB, lactate  which is 
shown in the next figure 3-38. 
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Figure 3-38 Schematic diagram of the pathways involving metabolites that were seen significantly 
higher in concentration in cancer induced group (T0) and control (C0). 
 A schematic diagram (pathway) was plotted on the basis of the metabolites found significantly 
higher in the lung cancer induced group (T0). The metabolites labeled in red are the ones that were 
higher in group T0. The profiled metabolited were identified with the pathways they were involved with. 
Here in this figure pyruvate, lactate, 2-OG, Succinate and fumarate are part of energy metabolism. 2-OB  
also enters the TCA cycle by getting ultimately getting converted to succinly CoA acting as a part of 
anaplerotic reaction. 
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Figure 3-39  Comparison between urinary concentration of Alanine between the groups T0 and C0. 
 The results shows the trend that curcumin in diet (group T2) will reduce the levels of alanine 
which is otherwise higher in case of lung cancer induced group (T0). Although it is not the significant 
difference but there is a trend seen between the groups T0 week 10, T0 week final and T2 week final. 
Alanine was significantly (* p < 0.05) hogher in cancer induced group (T0) as compared to control group 
(C0). Alanine is glucogenic amino acid which goes higher when there is need for glucose from non-sugar 
sources. 
 
 
 
 
 
 
 
 
 
T0 vs C0 WkF p = 
0.0132 
* 
* 
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Figure 3-40  Comparison between urinary concentration of Glycine between the groups T0 and C0. 
 The metabolite glycine is significantly higher (p < 0.05) in lung cancer induced group (T0) as 
compared to control group (C0). Glycine is a glucogenic amino acid which indicates group T0 is in energy 
criris and derives energy from non sugar carbon sources. 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
T0 vs C0 p = 0.0096 
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Figure 3-41 Comparison between urinary Concentration of Leucine between the groups T0 and C0. 
 There was a significant differences (p < 0.05) between the concentration of leucine between lung 
cancer induced group (T0) and control group C0. The leucine concentration was almost 100 times higher 
in T0 group than C0. Leucine is an amino acid. It is ketogenic amino acid.  More leucine means more 
ketone bodies which ultimately leads to more energy production although not efficient as glucogenic 
amino acid. Leucine enters TCA cycle by getting converted to acetyl CoA and thus generating ketone 
bodies if found in surplus amounts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
T0 vs C0 p = 0.0035 
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Figure 3-42 Comparison of urinary Concentration of Glutamine between the groups T0 and C0. 
 Glutamine is a glucogenic amino-acid. The concentration of glutamine is significantly different 
among different groups. Lung cancer induced group (T0) showed significantly higher concentration of 
glutamine when compared to control group (C0) (a, * p < 0.05). Results from comaprsion between lung 
induced cancer group (T0) and lund induced + curcumin in diet group (T2) significantly  (c, * p < 0.05) 
reduces  the levels glutamine . This indicats that cucumin in the diet does help to reduce the levels of  
metabolite that is otherwise higher in lung cancer. There was also significant difference (b, * p < 0.05) 
between group T2 and control group C0.  The concentration of glutamine was highest in T0 group and 
lowest in control group (C0), curcumin tends to alleviate the condition and is somewhat in the middle of 
the two groups. Colums with same letters are significantly different. 
 
 
 
 
 
 
 
 
 
T0 vs C0 (a) p = 0.0081 
T2 vs C0 (b) p = 0.0172 
T0 vs T2 (c) p = 0.0167 
 
 b c   
a b   
a c   
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Figure 3-43 Comparison of urinary Serine concentration between the groups T0 and C0. 
 The concentration of Serine was significantly higher (* p < 0.05) in lung cancer induced group 
(T0) as compared to control group (C0). Serine is also a glucogenic amino acid and can be used as 
substitute as energy from non-sugar carbon source.  
  
  
 
 
 
 
 
 
 
 
 
* 
T0 vs C0 p= 0.025 
* 
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Figure 3-44 Comaprison of urinary Proline Concentration between the groups T0 and C0. 
 The proline concentration in lung cancer induced group (T0) is significantly higher ( * p < 0.05) 
than control group (C0). Proline is glucogenic amino acid and can serve a energy source during 
gluconeogenesis. 
  
  
 
 
 
 
 
 
 
 
* 
* 
T0 vs C0 p = 0.0015 
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Figure 3-45 Comparison of urniany Threonine concentration between the groups T0 and C0. 
 Threonin is glucogenic amino acid which gets converted to pyruvate and thus enters the 
gluconeogenesis pathway. The concentration of threonine was significantly (* p < 0.05) higher in the lung 
cancer induced group (T0) than control group (C0). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
T0 vs C0 p = 0.047 
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 The results showed (figure 3-39 to 3-45)  that the  metabolites leucine,glutamine, 
proline, alanine, serine, glycine and threonine were significantly higher in the lung 
cancer induced group (T0) as compared to control group (C0). The curcumin in the diet 
tends to lower the metabolites higher in lung cancer as seen from the results (figure 3-
39 and figure 3-42). The group (T2) which had 2% curcumin in the diet showed a trend 
in the decrease in concentration of metabolites that were otherwise higher in 
concentration in lung cancer group (T0). All these metabolites are either ketogenic 
(leucine) or glucogenic (glutamine,proline,alanine, glycine, serine and threonine). 
Leucine gets converted to acetyl CoA and enters the TCA cycle pathway. If production 
of acetyl CoA exceeds concentration of oxaloacetate, the  extra acetyl CoA will get 
converted to ketone bodies which can also be used as energy source. The amino acids 
alanine, serine, glycine, threonine (glucogenic) get converted to pyruvate and enter the 
gluneogenesis pathway to get energy from non-sugar carbon source. The amino acids 
glutamine and proline (glucogenic) gets converted to glutamate which enters TCA cycle 
via alpha ketoglutarate (2-OG) and replinshes the TCA cycle acting as anaplerotic 
reaction. The figure 3-46 illustrates all these pathways. 
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Figure 3-46  Schematic illustration of glucogenic and ketogenic pathways. 
 The figure shows the profiled amino acid their involvement in the  glucogenic and ketogenic 
pathways.  The amino acids alanine, glycine, serine and threonine enter gluconeogenesis pathway or 
TCA cycle  by getting converted to pyruvate. The amino acid glutamine and proline first gets converted to 
glutamine which can then enter TCA cycle by getting converted to alphs KG (2-OG) this replinshes the 
TCA cycle intermediate products. The amino acid leucine gets converted to acetoacetyl CoA which can 
either directyly go for ketone  body formation or it can get converted to acety CoA and then enter TCA 
cycle or may get converted to ketone bodies if it exceeds the concentration of oxaloacetate present in the 
TCA cycle. 
  
 
 
Principles of Biochemistry “Lehninger” 
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Figure 3-47 Comparison of urinary 2-Methylglutarate (2-MG) concentration between the groups T0, 
T2 and C0. 
 The figure shows the urinary concentration of 2-MG. There was significant difference between T0 
and C0 and T2 and C0. The group T0 had  significantly higher (a, * p < 0.05) concentration of 2-MG than 
control group (C0) and group T2 too had significantly higher (b, * p < 0.05) concentration of 2-MG than 
control group (C0). Group T2 had 2% curcumin in their diet and the results show that curcumin can 
reduce the concentration of 2-MG as compared to lung cancer induced group (T0), although it is not 
statistically significant but there is a trend and this trend was seen for other metabolites too if not all. 
 
 
 
 
 
 
 
a b * 
a* 
b * 
T0 vs C0 (a) p =  0.027 
T2 vs C0 (b) p  =  0.03  
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Figure 3-48 Comaprison of urinary 3-Hydroxybutyrate (3-HB) concentration between the groups T0 
and C0. 
 The figure shows the concentration of urinary 3-HB between the lung cancer induced group (T0) 
and control group (C0). Group T0 has significantly higher (* p < 0.05) concentration of 3-HB than C0 
group. The metabolite 3-HB is a ketone body, produced because of the over production acetyl CoA. 
Ketone bodies can be a good source of energy especially for brain. 
 
  
 
 
 
 
 
 
 
 
 
 
* 
 * 
T0 vs C0 p = 0.0257  
* 
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Figure 3-49 Comparison between urinary 5-Hydroxylysine (5-HL) metabolite concentration 
between the groups T0 and C  
The lung cancer induced group (T0) had signfificantly (* p < 0.05) higher concentration of urinary 
metabolite 5-HL than the control group (C0). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 * 
 * 
 T0 vs C0 p =  0.0108  
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Figure 3-50 Urinary concentration of Acetamide,  comaprsion between the groups T0 and C0. 
 The concentration of urinary acetamide was significantly higher (*  p< 0.05) in lung cancer 
induced group (T0) than control (C0). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 * 
 * 
 T0 vs C0 p = 0.0093 
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Figure 3-51  The comparison of urinary concentration of Betaine between the groups T0 and C0. 
  The figure shows the concentration of urinary betaine which is significantly (* p < 0.05) higher in 
lung cancer induced group (T0) than control group (C0). 
 
 
 
 
 
 
 
 
 
 
 
 * 
 * 
       T0 vs C0 p  = 0.024 
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Figure 3-52 The comparison of urinary choline concentration between the groups T0 and C0. 
 The urinary choline concentration was significantly (* p < 0.05) higher in lung cancer induced 
group than control group. 
 
 
 
 
 
 
 
 
 
 
 
 * 
 * 
       T0 vs C0 p = 0.021 
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Figure 3-53 Comaprison of urinary metabolite glycerol between then groups T0 and C0. 
 The concentration of urinary glycerol was significantly (* p < 0.05) higher in lung cancer induced 
group than the control group (C0). 
 
 
 
 
 
 
 
 
 
 
 
 * 
 * 
           T0 vs C0 p  = 0.0121 
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Figure 3-54 Comparison of urinary metabolite glycolate between the groups T0 and C0. 
 The concentration of glycolate was significantly (* p < 0.05) lower in lung cancer induced group 
(T0) then control group( C0). This was the first and only urinary metabolite that was seen significantly 
lower in lung cancer, rest all the significantly different urinary metabolites were higher in lung cancer 
induced group (T0). 
 
 
 
 
 
 
 
 
 
 
 * 
 * 
     T0 vs C0 p = 0.043 
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Figure 3-55 Comparison of urinary metabolite glycylproline between the groups T0 and C0. 
 
 The concentration of glycylproline was significantly ( * p < 0.05) higher in lung cancer induced 
group (T0) than control group (C0). 
  
 
 
 
 
 
 
 
 
 
 
 
 * 
 * 
    T0 vs C0 p =  0.0268 
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Figure 3-56 Comparison of urinary metabolite histamine between the groups T0, T2 and C0. 
 
 The concentration of urinary metabolite histamine was significantly different between group T0 
and C0 and T2 and C0. Histamine is a metabolite usually related to immune response like inflammation. It 
is known that curcumin has a property to reduce inflammation and the results validatd it. The figure shows 
the lung cancer induced group (T0) has significantly (* a, p < 0.05) higher concentration of urinary 
histamine than control group. There was significant  (*b, p < 0.05) difference between group T2 (lung 
cancer induced + curcumin in diet) and control group (C0). There was no significant difference between 
group T0 and T2 but there was trend. T2 had lower concentration of histamine as compared to T0 which 
validates the fact that curcumin can alleviate inflammation. 
 
 
 
 
 
 
 
 
a,b  * 
b * 
a * 
   T 0 vs C0 ( a ) p = 0.034 
    T2 vs C0 ( b ) p = 0.037  
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Figure 3-57 Comaprison of urinary metabolite sarcosine between the groups T0 and C0. 
 
 The urinary metabolite sarcosine was significantly (* p < 0.05) higher in lung cancer induced 
group (T0) than control group (C0). 
 
 
 
 
 
 
 
 
 
 
 
 
 * 
 * 
   T0 vs C0 p = 0.02 
 * 
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Figure 3-58 Comparison of urinary metabolite serotonin between the groups T0 and C0. 
 
  There was significant difference between the two groups. The urinary metabolite serotonin was 
significantly (* p < 0.05) higher in lung cancer induced group (T0) than control group (C0).  
 
 
 
 
 
 
 
 
 
 
 
 
 
         T0 vs C0 p = 0.0258  
 
 * 
 * 
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Figure 3-59 Comparison between urinary metabolite taurine between the groups T0 and C0. 
  
  The concentration of urinary metabolite was significantly (* p < 0.05) higher in lung cancer 
induced group than  then control group (C0). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 * 
 * 
     T0 vs C0 p = 0.0015 
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Figure 3-60 Comparison of urinary metabolite trimethyamine N-oxide between the groups T0 and 
C0. 
 
  The lung cancer induced group (T0) had significantly (* p < 0.05) higher concentration of urinary 
metabolite trimethylamine N-oxide than control group (C0) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 * 
 * 
 T0 vs C0 p = 0.0078 
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Validation 
 There were no known biochemical assays for most the metabolites that 
were quantified so a unique approach was followed. All the quantified 
metabolites were validated by using SIMCA P+ 12.0 software. All the data for 
significantly different metabolites from chenomx were imported to SIMCA P+ 12.0 
software for MVDA. PCA and corresponding loading plots were plotted. The 
results of PCA plots showed that there was clear separation between lung cancer 
induced group (T0) and control group (C0). The corresponding loading plots 
validated the PCA plots and Chenomx data (Figure 3-61 to 3-66). Both PCA and 
loading plots validated data acquired from a Chenomx which suggests that the 
effects we saw in Chenomx were real. 
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Figure 3-61 Validation of metabolite quantification data (Chenomx) by PCA score plot 
 All the 68 metabolites profiled were imported as a excel sheet in the SIMCA P+ software for 
MVDA. PCA plot was plotted for validation of Chenomx Data.  The red triangles represent group T0, light 
brown boxes indicate group T2 and green dots represent group C0. The plot shows very clear separation 
between then groups T0 and C2. Group T2 is somewhere inbetween the groups, more drawn towards the 
control group indicating their profiles are much similar to control groups as compared T0 (Lung cancer 
group). This trend was also seen in figures from chnomx data. 
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Figure 3-62 Validation of metabolite quantification data (Chenomx) by PCA score plot. 
Comparison between group T0 and C0 
 The PCA plot for T0 and C0 showed clear separation between the two groups. The red triangles 
represent T0 and and green dots represent group C0. The same pattern was in the metabolite 
quantification data thus validating the it.  
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Figure 3-63 Loading Plot for C0 vs T0 
 The loading plot showed the metabolites that were responsible for the separation between two 
groups. In this loading plot allantoin and glycine are the main two metaboliotes which are responsible for 
the separation. The glycine is pushing the whole metabolites to one corner making it the itself strong 
metabolite against others. Removing of glycine might help to see other important significant metabolites. 
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Figure 3-64 PCA plot for T0, T2 and C0 after removing some of the metabolites. 
 Some of the metabolites (glycine, tartarate, alanine and lactate)  had too much strong effect on 
the whole profile of the groups. Those metabolites were removed and PCA was conducted. The PCA plot 
still looked the same. That means there are more metabolites than these ones which are responsible for 
the separation. 
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Figure 3-65 PCA plot between C0 and T0 after removal of some metabolites from the data set. 
 The metabolites glycine, tartarate, alanine and lactate were removed and PCA was conducted. 
There was still good separation between the groups indicating that there are more metabolites than those 
removed responsible for the separation. The control group is much tighter or close than treatment (T0) 
group indicating that control has less variation (standard deviation) than the T0. 
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Figure 3-66 Corresponding loding plot  (figure 3-65). T0 vs C0 
 The loading plot validates the results of chenomx. Betaine, glycerol, alanine, glutamine, 
threonine, taurine etc. are some of the few metabolites that are responsible for the separation between 
the group T0 (lung cancer induced) and control group C0. All these metabolites were seen significantly 
different in the chenomx data too thus these plots very well validate the data. There was only one 
metabolite (glycolate) that was higher in the control group as seen in chenomx data. The loading plot 
clearly shows that glyolate  is an important metabolite but in the opposite direction to the others validating 
the chenomx data. Alll the metabolites that were higher in the lung cancer group (T0) arr towards right 
quadrant of the plot and the metabolites that were higher in the control group are shown in the left 
quadrant of the plot. This data signifies that the effect is real and true. Hence validated. 
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Summary Specific aim 3 
The metabolite quantification data established that there were significant 
differences between the metabolites of T0 and C0 group. Some of the estimated 
metabolites have already been known to play some direct or indirect role in 
cancer. Metabolites involved in energy metabolism were mostly higher in the 
cancer induced group. The metabolite quantification (chenomx) data was well 
validated, indicating that the effects seen were real. 
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Chapter 4: Discussion 
 Cancer is the second leading cause of death in the Unites States, after 
cardiovascular disease [14]. Cancer care for US patients costs roughly about $72.1 
billion, with higher costs for lung and colorectal cancer compared with breast and 
prostate cancer [17]. According to latest survey by United States Cancer Statistics 
(USCS) there are more deaths due to lung cancer than any other type of cancer. In the 
United States in 2007, 203,536 people were diagnosed with lung cancer, and 158,683 
people died from it (1999–2007 Cancer Incidence and Mortality Data, CDC). The 
National Cancer Institute’s budget (2009) was $ 4.97 billion and additional $ 1.26 billion 
for recovery and reinvestment (AARA) out of which $246.9 million were spent on lung 
cancer research last year and still lung cancer is the leading cause of cancer deaths in 
United States. Using new research approaches (e.g. metabolomics) shows promising 
results in determining the early potential biomarkers for lung cancer which would reduce 
the cost and will help to curb the disease before it spreads.  Out of total FDA approved 
cancer drugs in the market, 70% of them are from plant origin [24]. Phytochemicals in 
the plants show promising results to cure and/or prevent the cancer. Curcumin is one of 
the dietary phytochemicals that proved to be most effective against cancer [12]. 
Combining both schools of thoughts, metabolomics approach and dietary intervention 
with curcumin would be a better approach to target the lung cancer and there is enough 
evidence from the results of the present study to support the hypothesis.  
 Golden Syrian hamsters were selected for this study and cancer was induced 
with subcutaneous weekly injections of a chemical carcinogen BOP. In addition to it 
curcumin was added in the diet to check whether curcumin can alleviate the condition 
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(lung cancer). The results showed that BOP successfully induced lung cancer and 
addition of curcumin reduced cancer incidence. From the histological studies the 
incidence of lung cancer in the group T0 (BOP induced) was 45.5% whereas the group 
that was given BOP and then curcumin in the diet, the incidence of lung cancer was 
11.1%. Even there was less inflammation in the control group that was given curcumin 
in the diet throughout the study (C2) when compared to regular control group (C0) and 
other four groups (T0, T2, P0 and P2). This could be attributed to the fact that curcumin 
does show properties of interacting with the molecular signal involved with the cancer 
progression directly (anti-carcinogenic properties) or indirectly (via anti-oxidant, anti-
inflammatory etc.) [16, 25, 27, 32]  There was chronic inflammation in the group T2 
(BOP + curcumin in diet). There could be several reasons for this, it is possible that 
group T2 had been initiated to cancer but curcumin intervention reverted the cells back 
to normal and healhty. Chronic inflammation could be result of getting better from 
worse. But this could not be proved since all the histological slides were terminal slides. 
There should have been some slides from before curcumin intervention, during the 
process and at the end that would have helped to explain chronic inflammation in the 
group T2 in a better way. It is also possible that group T2 never got cancer at any point 
of time of the study, curcumin would have helped to alleviate the condition and thus 
struggle between the two conditions would have resulted in chronic inflammation which 
is always better than cancer. 
 There was no difference in diet intake between the groups but the animals in the 
group that were induced lung cancer (T0) showed significant reduction in body weight. 
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The results from DNA damage (comet assay) show that curcumin has protective effect. 
The group T0 (BOP induced) had significant amount of DNA damage as compared to 
control group and group T2 (BOP induced + curcumin in the diet). There was DNA 
damage in the group T2 but it was significantly lower than the group T0, which again 
adds to the facts of curcumin’s role as DNA protective agent [38]. 
 MVDA of NMR data showed very clear separation between the control groups 
(C0, C2), cancer induced group (T0) and cancer induced + curumin group (T2). PCA 
scores plots showed significant separation/differences between the groups T0 and C0. 
Each score or observation in the score plot represents each individual urine NMR data. 
All the scores that belong to one group were close to each other and well separated 
from other group along the first component (t1) and/or second component (t2). The PCA 
score plots signified that these groups were different to each other or in other words the 
urinary NMR profile was different between the two groups. The corresponding loading 
plots showed the parts of the spectrum that are responsible for the separation between 
the two groups. The parts of spectrum could directly be related to the metabolite peaks 
around that area of spectrum and thus loading plot could tell us what metabolite peaks 
are different. The loading plot tells us what makes them different but not by how much 
they are different. It is a qualitative result. MVDA of urinary NMR data established that 
the groups were different (PCA score plot) and the parts of spectrum/metabolite peaks 
responsible for the differences/separation between the groups (loading plot).  PLS data 
showed strong correlation between the urinary NMR profile and DNA damage. The DNA 
damage data (comet assay) was considered as y-parameter and it was correlated 
against urinary NMR data as x-axis. The data signifies that there are some metabolites 
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in the urine samples that could detect changes in DNA of lung tissue. It could be any 
metabolites that are already known (nucleotides, 8-OHdG etc) [39] and are related to 
DNA damage or some new metabolite/s which was never before related to DNA 
damage. The PLS plot even showed nice separation of two groups (T0 and T2) along 
the regression line.  
 The metabolites were quantified by the chenomx NMR suit 5.1 software. 
Chenomx has a database of 292 urinary metabolites which were compared and 
matched with the acquired NMR data. Out of 296 metabolites, 68 were found different 
between then groups T0 and C0. Further, statistical analysis of 68 profiled metabolites 
revealed that 27 metabolites out of 68 metabolites were significantly (p<0.05) different 
between the group T0 and C0. All the significantly different metabolites were higher in 
cancer induced group (T0) than control group C0 except for the metabolite glycolate 
which was higher in C0 group than T0. At present there is no possible reason which 
would define higher levels of glycolate in control groups. Glycolate is usually produced 
in plants during photo-respiration and can be utilized by some bacteria [40, 41].  
 Pyruvate, lactate, 2-oxoglutarate, succinate, fumarate and 2-oxobutyrate were 
seen significantly higher in T0 group. These metabolites could be traced back to energy 
metabolism. This indicates that the cells are growing rapidly and are in constant 
demand of energy. 2-oxobutyrate is converted to propionyl CoA  malonyl CoA 
succinyl CoA  (KEGG) which can enter kreb’s cycle thus replenishing TCA 
intermediates for more energy production. 2-OB is also involved with propionate 
metabolism and in the metabolism of many amino acids (glycine, methionine, valine, 
leucine, serine, threonine, isoleucine. If 2-OB has higher concentration than these 
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amino acids might have higher concentration too. Most of the pyruavte from glycolysis is 
converted to lactate for faster energy production and thus TCA needs to be replenished 
which could be conducted by anaplerotic reactions.  There have been studied that 
showed lactate and alanine can serve as biomarker for prostate and colorectal cancer 
[42, 43]. The higher levels of 2-OG has also been seen higher in acute myelogenous 
leukemia [44]. Succinate was seen in higher concentration too and it has been reported 
that succinate can increase expression of genes that facilitate angiogenesis, metastasis 
and glycolysis, ultimately leading to tumor progression [45]. There were higher levels of 
alanine, glutamine, glycine, leucine, serine, proline and threonine. All these are amino 
acids both glucogenic and ketogenic.  Alanine, glycine, serine and threonine are 
glucogenic amino acids. These amino acids get converted to pyruvate and then  
pyruvate can either go for acetyl CoA or it can go for glucose synthesis from non-sugar 
carbon (gluconeogenesis).  Leucine is a ketogenic amino acid. It gets converted to 
acetoacetyl CoA which can further either get converted to ketone bodies or to acetyl 
CoA. The acetyl CoA will further enter TCA but the amount of acetyl CoA that enters 
TCA is regulated by the amount of oxaloacetate (OAA) present in the TCA cycle. If 
there is more acetyl CoA than OAA then the rest of the surplus acetyl can get converted 
to ketone bodies, so higher amount of leucine might result in higher amount of ketone 
bodies after meeting TCA cycle demands. Glutamine and proline are glucogenic amino 
acids too but they first get converted to glutamate and then glutamate can enter TCA 
cycle by getting converted to alpha-ketoglutatrate (2-OG). Most of these profiled amino 
acids are directly or indirectly linked to the cancer. There are studies that have shown 
taurine, lactate, choline, inositol, glycine, phosphocholine, proline, phenylalanine, 
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alanine, threonine, valine and leucine were found to be more prevalent in colorectal 
cancer [42, 46-48]. All of these metabolite levels go higher in cancer except glutamine. 
Unlike our results glutamine is known to get depleted in cancer cells. Experimental 
evidence has indicated that glutamine is the major respiratory fuel for tumor cells [49]. If 
this is true then in cancer the levels of glutamine should be depleted but the results 
showed that glutamine was higher in the cancer induced group T0. 
 The other metabolites that were seen significantly higher in the cancer induced 
group were 2-methylglutarate (2-MG), 3-hydroxybutyrate (3-HB), 5-hydroxylysine, 
acetamide, betaine, choline, glycerol, glycylproline, histamine, sarcosine, serotonin, 
taurine and trimethyl N-oxide. 3-HB is a ketone body. It could be higher due to various 
reasons, results showed that leucine was higher too in the cancer group so more 
leucine might result to more ketone bodies. The cancer group T0 lost significant amount 
of weight even though there was no difference in diet intake. It was observed that the 
cancer induced group T0 had very less fat, when held in hand the rib cage and heart 
beat could be felt easily this could have been because of fat mobilization. When fat is 
oxidized acetyl CoA is the end product which can enter TCA cycle for energy production 
but too much amount of acetyl CoA can result in ketone body formation and thus group 
T0 had higher amounts of 3-HB. Histamine was seen higher in T0 and lower in the 
group T2 (induced with cancer + curcumin) and lowest in the control group C0. 
Histamine is known to be higher during inflammation and curcumin is known to have 
anti-inflammatory property [50]. The results clearly validate the fact that cucumin can 
reduce inflammation although the difference between the groups T0 and T2 was not 
significant but a trend can be seen.  Sarcosine a modified amino acid was also seen 
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higher in the cancer group T0. It has been very well reported that sarcosine levels go 
higher during prostate cancer [51]. It has been established as a biomarker for prostate 
cancer and it is possible that it is higher in other cancers (e.g. lung cancer) too and not 
only in prostate cancer. Serotonin (5-HT) was also seen higher in cancer group T0. It 
has been shown that if there is uncoupling of homeostatic regulation of 5-HT in 
mammary epithelium, the higher levels of 5-HT will favor breast cancer [52]. 
 All these metabolites were quantified in chenomx and to validate these 
metabolites a unique approach was followed. Multivariate data analysis (MVDA) of 
chenomx data validated the results. The MVDA showed the clear separation between 
the cancer group T0 and control group C0 (PCA score plot). The loading plot showed us 
the metabolites that were responsible for the separation, which showed the same 
metabolites found different in chenomx data and thus the data was validated. 
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Future Directions: 
 All the profiled metabolites that were significantly different could be potential 
early biomarkers. Further, validation and estimation of these metabolites in the tissues 
and blood might give important information about the progression of the cancer. These 
probable biomarkers could be further tested and validated in serum and/or tissue by 
biochemical assays or any relevant spectroscopic assay (GC-MS, LC-MS etc.) 
techniques. 
 Genetic analysis of specific genes for particular metabolite will help us to know 
about the expression levels. Effect of curcumin on specific genes might help to 
understand the mechanism of action of curcumin with regard to that particular 
metabolite. 
The metabolites that were seen higher in lung cancer might be specific for lung 
cancer or it might be higher in any other cancer too e.g. sarcosine was seen higher in 
prostate cancer but we saw it higher in lung cancer too so further analysis of these 
metabolites should be conducted with respect to cancer in general and not specific to 
one cancer.  
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Lung cancer is the leading cause of cancer deaths in the US, in part due to poor 
diagnosis. Prognosis can be improved, if detected at an early stage. The objective of 
this study was to use the metabolomic approach to investigate early potential 
biomarkers for lung cancer. Golden Syrian hamsters were randomized into groups 
(treatment. prevention and control). Lung cancer was induced in treatment group by a 
chemical carcinogen, N-nitrosobis-2-(oxopropyl) amine (BOP) while the control animals 
were injected with saline. Urine was collected weekly throughout the study and frozen at 
-800 C. Proton nuclear magnetic resonance (1H NMR) spectra, acquired using Varian 
500 MHz magnet were processed using ACD labs software. The processed, digitized 
NMR spectral data was analyzed using multivariate data analysis software, SIMCA P+. 
Principal Component Analysis (PCA) score plots showed clear significant (p < 0.05) 
separation between the cancer and control groups. The metabolites responsible for the 
differences between the groups as observed from the PCA loading plots were quantified 
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using CHENOMX NMR metabolite database. The metabolites (n=26) found to be 
significantly different (p<0.05) in the groups were traced back to their respective 
biochemical pathways in an effort to gain mechanistic insight into lung cancer 
progression from the metabolite view point.  Some of these metabolites such as glycine, 
sarcosine, and alanine have been previously reported to be increased in other cancer 
types like prostate. These could potentially serve as potential biomarkers of cancer in 
general. In addition, some metabolites may be of specific relevance to progression of 
lung cancer and may therefore be further explored as possible biomarkers of this 
aggressive cancer type.  
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